Document:

Unassociated Document

    
      

      

    

    
      

      

    

    EXHIBIT 10.28

    
      

      

    

     

    AMENDED
      AND RESTATED INVESTOR RIGHTS AGREEMENT

     

    This
      Amended and Restated Investor Rights Agreement (this “Agreement”) is made and
      entered into as of February 4, 2008, among Access Pharmaceuticals, Inc., a
      Delaware corporation (the “Company”), and each of the
      purchasers executing this Agreement and listed on Schedule 1 attached
      hereto (collectively, the “Purchasers”).

     

    This
      Agreement is being entered into pursuant to the Preferred Stock and Warrant
      Purchase Agreement, dated as of November 7, 2007, by and among the Company
      and
      the Purchasers, as amended.  The Company and certain of the Purchasers
      (such Purchasers, the “Original Purchasers”) entered
      into an Investor Rights Agreement, dated as of November 10, 2007 (the “Original Investor Rights
      Agreement”) in connection with entering into a Preferred Stock and
      Warrant Purchase Agreement dated as of November 7, 2007 (the “Original Purchase
      Agreement”).  On the date hereof, the Company, the requisite
      Original Purchasers and certain additional Purchasers have amended and restated
      the Original Purchase Agreement (the Original Purchase Agreement, as so amended
      and restated, the “Purchase
      Agreement”), and, in connection therewith, the Company and the Purchasers
      hereby amend and restate the Original Investor Rights Agreement as set forth
      below.

     

    The
      Company and the Purchasers hereby agree as follows:

     

    1.           Definitions.

     

    Capitalized
      terms used and not otherwise defined herein shall have the meanings given such
      terms in the Purchase Agreement. As used in this Agreement, the following terms
      shall have the following meanings:

     

    “Additional
      Closing” shall
      have the meaning assigned in Section 2.1(c) of the Purchase
      Agreement.

     

    “Advice”
shall
      have the
      meaning set forth in Section 3(m).

     

    “Affiliate”
means,
      with
      respect to any Person, any other Person that directly or indirectly controls
      or
      is controlled by or under common control with such Person. For the purposes
      of
      this definition, “control,” when used with respect to any Person, means the
      possession, direct or indirect, of the power to direct or cause the direction
      of
      the management and policies of such Person, whether through the ownership of
      voting securities, by contract or otherwise; and the terms of “affiliated,”
“controlling” and “controlled” have meanings correlative to the
      foregoing.

     

    “Blackout
      Period” shall have
      the meaning set forth in Section 3(n).

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

       

    

    “Board”
shall
      have the meaning
      set forth in Section 3(n).

     

    “Business
      Day” means any day
      except Saturday, Sunday and any day which shall be a legal holiday or a day
      on
      which banking institutions in the State of Texas generally are authorized or
      required by law or other government actions to close.

     

    “Commission”
means
      the
      Securities and Exchange Commission.

     

    “Common
      Stock” means the
      Company’s Common Stock, par value $0.01 per share.

     

    “Conversion
      Shares” means the
      shares of Common Stock issuable upon conversion of the Preferred Stock and
      Warrants purchased by the Purchasers pursuant to the Purchase Agreement,
      including, without limitation, shares of Common Stock issued in payment of
      dividends due on the Preferred Stock.

     

    “Effectiveness
      Date” means,
      with respect to the Initial Registration Statement required to be filed
      hereunder, the 60th
      calendar day following the Filing Date (or, in the event of a “review” by the
      Commission, the 90th calendar day following the Filing Date) and with respect
      to
      any additional Registration Statements which may be required pursuant to Section
      3(b), the 30th
      calendar day following the date on which an additional Registration Statement
      is
      required to be filed hereunder; provided, however,
      that in the
      event the Company is notified by the Commission that one or more of the above
      Registration Statements will not be reviewed or is no longer subject to further
      review and comments, the Effectiveness Date as to such Registration Statement
      shall be no later than the fifth trading day following the date on which the
      Company is so notified if such date precedes the dates otherwise required
      above.

     

    “Effectiveness
      Period” shall
      have the meaning set forth in Section 2.

     

    “Event”
shall
      have the meaning
      set forth in Section 7(e).

     

    “Exchange
      Act” means the
      Securities Exchange Act of 1934, as amended.

     

    “Filing
      Date” means the
      earlier of (i) the 30th day following the first Additional Closing Date and
      (ii)
      the 45th
      day
      following the date hereof and, with respect to any additional Registration
      Statements which may be required pursuant to Section 3(b), the earliest
      practical date on which the Company is permitted by SEC Guidance to file such
      additional Registration Statement related to the Registrable
      Securities.

     

    “Holder”
or
“Holders”
means
      the holder or
      holders, as the case may be, from time to time of Registrable Securities,
      including without limitation the Purchasers and their assignees.  For
      purposes of this Agreement, the holder or holders of Preferred Stock and
      Warrants shall be deemed to be holders of that number of shares of Registrable
      Securities into which such Preferred Stock and Warrants are convertible at
      the
      applicable time.

     

    “Indemnified
      Party” shall have
      the meaning set forth in Section 5(c).

     

    “Indemnifying
      Party” shall
      have the meaning set forth in Section 5(c).

     

    “Initial
      Registration
      Statement” means the initial Registration Statement which includes the
      Initial Shares filed pursuant to this Agreement.

     

    “Initial
      Shares” means a
      number of Registrable Securities equal to the lesser of (i) the total number
      of
      Registrable Securities and (ii) one-third of the number of issued and
      outstanding shares of Common Stock that are held by non-affiliates of the
      Company on the day immediately prior to the filing date of the Initial
      Registration Statement.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

       

    

    “Losses”
shall
      have the
      meaning set forth in Section 5(a).

     

    “Person”
means
      an individual
      or a corporation, partnership, trust, incorporated or unincorporated
      association, joint venture, limited liability company, joint stock company,
      government (or an agency or political subdivision thereof) or other entity
      of
      any kind.

     

    “Preferred
      Stock” means the
      Company’s Series A Cumulative Convertible Preferred Stock, par value $0.01 per
      share.

     

    “Proceeding”
means
      an action,
      claim, suit, investigation or proceeding (including, without limitation, an
      investigation or partial proceeding, such as a deposition), whether commenced
      or
      threatened.

     

    “Prospectus”
means
      the
      prospectus included in any Registration Statement (including, without
      limitation, a prospectus that includes any information previously omitted from
      a
      prospectus filed as part of an effective registration statement in reliance
      upon
      Rule 430A promulgated under the Securities Act), as amended or supplemented
      by
      any prospectus supplement, with respect to the terms of the offering of any
      portion of the Registrable Securities covered by such Registration Statement,
      and all other amendments and supplements to the Prospectus, including
      post-effective amendments, and all material incorporated by reference in such
      Prospectus.

     

    “Purchased
      Shares” means the
      shares of Preferred Stock purchased by the Purchasers pursuant to the Purchase
      Agreement, whether at the Initial Closing or an Additional Closing.

     

    “Registrable
      Securities” means
      (a) the Conversion Shares and the Warrant Shares (without regard to any
      limitations on beneficial ownership contained in the Preferred Stock or the
      Warrants and including, without limitation, Conversion Shares and Warrant Shares
      issued or issuable upon conversion or exercise (as applicable) of the Preferred
      Stock and Warrants issued in connection with an Additional Closing) or other
      securities issued or issuable to each Purchaser or its transferee or designee
      (i) upon conversion of the Purchased Shares and/or upon exercise of the
      Warrants, or (ii) upon any dividend or distribution with respect to, any
      exchange for or any replacement of such Purchased Shares, Conversion Shares,
      Warrants or Warrant Shares or (iii) upon any conversion, exercise or exchange
      of
      any securities issued in connection with any such distribution, exchange or
      replacement; or (iv) in connection with any anti-dilution provisions in the
      Certificate of Designation or the Warrants without giving effect to any
      limitations on conversion set forth in the Certificate of Designation or
      limitations on exercise set forth in the Warrants; (b) securities issued or
      issuable upon any stock split, stock dividend, recapitalization or similar
      event
      with respect to the foregoing; and (c) any other security issued as a dividend
      or other distribution with respect to, in exchange for, in replacement or
      redemption of, or in reduction of the liquidation value of, any of the
      securities referred to in the preceding clauses; provided, however, that such
      securities shall cease to be Registrable Securities when such securities have
      been sold to or through a broker or dealer or underwriter in a public
      distribution or a public securities transaction or when such securities may
      be
      sold without any restriction pursuant to Rule 144(k) as determined by the
      counsel to the Company pursuant to a written opinion letter, addressed to the
      Company’s transfer agent to such effect as described in Section 2 of this
      Agreement.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

       

    

    “Registration
      Statement” means
      the registration statements and any additional registration statements
      contemplated by Section 2, including (in each case) the Prospectus, amendments
      and supplements to such registration statement or Prospectus, including pre-
      and
      post-effective amendments, all exhibits thereto, and all material incorporated
      by reference in such registration statement.

     

    “Rule
      144” means Rule 144
      promulgated by the Commission pursuant to the Securities Act, as such Rule
      may
      be amended from time to time, or any similar rule or regulation hereafter
      adopted by the Commission having substantially the same effect as such
      Rule.

     

    “Rule
      158” means Rule 158
      promulgated by the Commission pursuant to the Securities Act, as such Rule
      may
      be amended from time to time, or any similar rule or regulation hereafter
      adopted by the Commission having substantially the same effect as such
      Rule.

     

    “Rule
      415” means Rule 415
      promulgated by the Commission pursuant to the Securities Act, as such Rule
      may
      be amended from time to time, or any similar rule or regulation hereafter
      adopted by the Commission having substantially the same effect as such
      Rule.

     

    “Rule
      424” means Rule 424
      promulgated by the Commission pursuant to the Securities Act, as such Rule
      may
      be amended or interpreted from time to time, or any similar rule or regulation
      hereafter adopted by the Commission having substantially the same purpose and
      effect as such Rule.

     

    “SEC
      Guidance” means (i) any
      publicly-available written or oral guidance, comments, requirements or requests
      of the Commission staff and (ii) the Securities Act.

     

    “Securities
      Act” means the
      Securities Act of 1933, as amended.

     

    “Special
      Counsel” means Wiggin
      and Dana LLP.

     

    “Warrants”
means
      the Common
      Stock purchase warrants issued pursuant to the Purchase Agreement, whether
      at
      the Initial Closing or an Additional Closing, including, without limitation
      the
      Placement Agent Warrants.

     

    “Warrant
      Shares” means the
      shares of Common Stock issuable upon the exercise of the Warrants (including,
      without limitation, the Placement Agent Warrants) issued or to be issued to
      the
      Purchasers or their assignees or designees in connection with the offering
      consummated under the Purchase Agreement.

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

       

    

    2.           Registration.
      As soon
      as possible following the first Additional Closing Date (but not later than
      the
      Filing Date), the Company shall prepare and file with the Commission a “shelf”
Registration Statement for the resale of all or such maximum portion of the
      Registrable Securities as permitted by SEC Guidance (provided that the Company
      shall use diligent efforts to advocate with the Commission for the registration
      of all of the Registrable Securities in accordance with the SEC Guidance,
      including without limitation, the Manual of Publicly Available Telephone
      Interpretations D.29) that are not then registered on an effective Registration
      Statement for an offering to be made on a continuous basis pursuant to Rule
      415.
      The Registration Statement shall be on Form S-3 (or if such form is not
      available to the Company on another form appropriate for such registration
      in
      accordance herewith). The Company shall use its best efforts to cause the
      Registration Statement to be declared effective under the Securities Act not
      later than ninety (90) days after the Filing Date (including filing with the
      Commission a request for acceleration of effectiveness in accordance with Rule
      461 promulgated under the Securities Act within five (5) Business Days of the
      date that the Company is notified (orally or in writing, whichever is earlier)
      by the Commission that a Registration Statement will not be “reviewed,” or not
      be subject to further review) and to keep such Registration Statement
      continuously effective under the Securities Act until such date as is the
      earlier of (x) the date when all Registrable Securities covered by such
      Registration Statement have been sold or (y) with respect to such Holder, such
      time as all Registrable Securities held by such Holder may be sold without
      any
      restriction pursuant to Rule 144(k) as determined by the counsel to the Company
      pursuant to a written opinion letter, addressed to the Company’s transfer agent
      to such effect (the “Effectiveness
      Period”).  The Company shall telephonically request
      effectiveness of a Registration Statement as of 5:00 p.m. New York City time
      on
      a Trading Day.   The Company shall immediately notify the Holders
      via facsimile or by e-mail of the effectiveness of a Registration Statement
      on
      the same Trading Day that the Company telephonically confirms effectiveness
      with
      the Commission, which shall be the date requested for effectiveness of such
      Registration Statement.  The Company shall, by 9:30 a.m. New York City
      time on the Trading Day after the effective date of such Registration Statement,
      file a final Prospectus with the Commission as required by Rule
      424.   For purposes of the obligations of the Company under this
      Agreement, no Registration Statement shall be considered “effective” with
      respect to any Registrable Securities unless such Registration Statement lists
      the Holders of such Registrable Securities as “Selling Stockholders” and
      includes such other information as is required to be disclosed with respect
      to
      such Holders to permit them to sell their Registrable Securities pursuant to
      such Registration Statement, unless any such Holder is not included as a
“Selling Stockholder” pursuant to Section 3(m).  Such Registration
      Statement also shall cover, to the extent allowable under the Securities Act
      and
      the Rules promulgated thereunder (including Securities Act Rule 416), such
      indeterminate number of additional shares of Common Stock resulting from stock
      splits, stock dividends or similar transactions with respect to the Registrable
      Securities.  Notwithstanding the foregoing or any other provision of
      this Agreement, and subject to the payment of liquidated damages pursuant to
      Section 7(e), if any SEC Guidance sets forth a limitation on the number of
      Registrable Securities permitted to be registered on a particular Registration
      Statement (and notwithstanding that the Company used diligent efforts to
      advocate with the Commission for the registration of all or a greater portion
      of
      Registrable Securities), unless otherwise directed in writing by a Holder as
      to
      its Registrable Securities, the number of Registrable Securities to be
      registered on such Registration Statement will first be reduced by the Common
      Stock underlying the Placement Agent Warrants and second by Registrable
      Securities represented by Warrant Shares (applied, in the case that some Warrant
      Shares may be registered, to the Holders on a pro rata basis based on the total
      number of unregistered Warrant Shares held by such Holders); provided, however,
      that, prior to any reduction in the number of Registrable Securities included
      in
      a Registration Statement as set forth in this sentence, the number of shares
      of
      Common Stock that are not Registrable Securities and which shall have been
      included on such Registration Statement shall be reduced by up to
      100%.

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

       

    

    3.           Registration
      Procedures.

     

    In
      connection with the Company’s registration obligations hereunder, the Company
      shall:

     

    (a)
      Prepare and file with the Commission on or prior to the Filing Date, a
      Registration Statement on Form S-3 (or if such form is not available to the
      Company on another form appropriate for such registration in accordance
      herewith) (which shall include a Plan of Distribution substantially in the
      form
      of Exhibit A
      attached hereto), and cause the Registration Statement to become effective
      and
      remain effective as provided herein; provided, however, that not less than
      three
      (3) Business Days prior to the filing of the Registration Statement or any
      related Prospectus or any amendment or supplement thereto, the Company shall
      (i)
      furnish to the each Holder and the Special Counsel, copies of all such documents
      proposed to be filed, which documents (other than those incorporated by
      reference) will be subject to the review of such Special Counsel, and (ii)
      at
      the request of any Holder cause its officers and directors, counsel and
      independent certified public accountants to respond to such inquiries as shall
      be necessary, in the reasonable opinion of counsel to such Holders, to conduct
      a
      reasonable investigation within the meaning of the Securities Act. The Company
      shall not file the Registration Statement or any such Prospectus or any
      amendments or supplements thereto to which the Holders of a majority of the
      Registrable Securities or the Special Counsel shall reasonably object within
      three (3) Business Days after their receipt thereof.  In the event of
      any such objection, the Holders shall provide the Company with any requested
      revisions to such prospectus or supplement within two (2) Business Days after
      such objection.

     

    (b)           (i)
      Prepare and file with the Commission such amendments, including post-effective
      amendments, to the Registration Statement as may be necessary to keep the
      Registration Statement continuously effective as to the applicable Registrable
      Securities for the Effectiveness Period and to the extent any Registrable
      Securities are not included in such Registration Statement for reasons other
      than the failure of the Holder to comply with Section 3(m) hereof, shall prepare
      and file with the Commission such amendments to the Registration Statement
      or
      such additional Registration Statements as are appropriate in order to register
      for resale under the Securities Act all Registrable Securities; (ii) cause
      the
      related Prospectus to be amended or supplemented by any required Prospectus
      supplement, and as so supplemented or amended to be filed pursuant to Rule
      424
      (or any similar provisions then in force) promulgated under the Securities
      Act;
      (iii) respond as promptly as reasonably practicable, and in no event later
      than
      ten (10) Business Days to any comments received from the Commission with respect
      to the Registration Statement or any amendment thereto and as promptly as
      reasonably practicable provide the Holders true and complete copies of all
      correspondence from and to the Commission relating to the Registration
      Statement, but not, without the prior written consent of the Holders, any
      comments that would result in the disclosure to the Holders of material and
      non-public information concerning the Company; and (iv) comply in all material
      respects with the provisions of the Securities Act and the Exchange Act with
      respect to the disposition of all Registrable Securities covered by the
      Registration Statement during the applicable period in accordance with the
      intended methods of disposition by the Holders thereof set forth in the
      Registration Statement as so amended or in such Prospectus as so supplemented.
      Subject to the payment of any liquidated damages that may be payable pursuant
      to
      Section 7(e), the Company shall not be deemed to be in breach of this Section
      3(b) if it fails to register any Registrable Securities or file a Registration
      Statement, in either case, in order to comply with any SEC Guidance; provided
      that the Company uses diligent efforts to advocate with the Commission for
      the
      registration of all or a greater portion of Registrable Securities.

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

       

    

    (c)           Notify
      Holders of Registrable Securities to be sold and the Special Counsel as promptly
      as reasonably practicable (A) when a Prospectus or any Prospectus supplement
      or
      post-effective amendment to the Registration Statement is proposed to be filed
      (but in no event in the case of this subparagraph (A), less than three (3)
      Business Days prior to date of such filing); (B) when the Commission notifies
      the Company whether there will be a “review” of such Registration Statement and
      whenever the Commission comments in writing on such Registration Statement;
      and
      (C) with respect to the Registration Statement or any post-effective amendment,
      when the same has become effective, and after the effectiveness thereof: (i)
      of
      any request by the Commission or any other Federal or state governmental
      authority for amendments or supplements to the Registration Statement or
      Prospectus or for additional information; (ii) of the issuance by the Commission
      of any stop order suspending the effectiveness of the Registration Statement
      covering any or all of the Registrable Securities or the initiation of any
      Proceedings for that purpose; (iii) of the receipt by the Company of any
      notification with respect to the suspension of the qualification or exemption
      from qualification of any of the Registrable Securities for sale in any
      jurisdiction, or the initiation or threatening of any Proceeding for such
      purpose; and (iv) if the financial statements included in the Registration
      Statement become ineligible for inclusion therein or of the occurrence of any
      event that makes any statement made in the Registration Statement or Prospectus
      or any document incorporated or deemed to be incorporated therein by reference
      untrue in any material respect or that requires any revisions to the
      Registration Statement, Prospectus or other documents so that, in the case
      of
      the Registration Statement or the Prospectus, as the case may be, it will not
      contain any untrue statement of a material fact or omit to state any material
      fact required to be stated therein or necessary to make the statements therein,
      in the light of the circumstances under which they were made, not
      misleading.  Without limitation to any remedies to which the Holders
      may be entitled under this Agreement, if any of the events described in Section
      3(c)(C)(i), 3(c)(C)(ii), 3(c)(C)(iii) or 3(c)(C)(iv) occur, the Company shall
      use its best efforts to respond to and correct the event.

     

    (d)           Use
      its best efforts to avoid the issuance of, or, if issued, use best efforts
      to
      obtain the withdrawal of, (i) any order suspending the effectiveness of the
      Registration Statement or (ii) any suspension of the qualification (or exemption
      from qualification) of any of the Registrable Securities for sale in any
      jurisdiction, at the earliest practicable time.

     

    (e)           If
      requested by any Holder of Registrable Securities, (i) promptly incorporate
      in a
      Prospectus supplement or post-effective amendment to the Registration Statement
      such information as the Company reasonably agrees should be included therein
      and
      (ii) make all required filings of such Prospectus supplement or such
      post-effective amendment as soon as reasonably practicable after the Company
      has
      received notification of the matters to be incorporated in such Prospectus
      supplement or post-effective amendment.

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

       

    

    (f)           Furnish
      to each Holder and the Special Counsel, without charge, at least one conformed
      copy of each Registration Statement and each amendment thereto, including
      financial statements and schedules, and all exhibits to the extent requested
      by
      such Person (including those previously furnished or incorporated by reference)
      promptly after the filing of such documents with the Commission.

     

    (g)           Promptly
      deliver to each Holder and the Special Counsel, without charge, as many copies
      of the Prospectus or Prospectuses (including each form of prospectus) and each
      amendment or supplement thereto as such Persons may reasonably request; and
      the
      Company hereby consents to the use of such Prospectus and each amendment or
      supplement thereto by each of the selling Holders in connection with the
      offering and sale of the Registrable Securities covered by such Prospectus
      and
      any amendment or supplement thereto.

     

    (h)           Prior
      to any public offering of Registrable Securities, use its best efforts to
      register or qualify or cooperate with the selling Holders and the Special
      Counsel in connection with the registration or qualification (or exemption
      from
      such registration or qualification) of such Registrable Securities for offer
      and
      sale under the securities or Blue Sky laws of such jurisdictions within the
      United States as any Holder requests in writing, to keep each such registration
      or qualification (or exemption therefrom) effective during the Effectiveness
      Period and to do any and all other acts or things necessary or advisable to
      enable the disposition in such jurisdictions of the Registrable Securities
      covered by a Registration Statement; provided, however, that the Company shall
      not be required to qualify generally to do business in any jurisdiction where
      it
      is not then so qualified or to take any action that would subject it to general
      service of process in any jurisdiction where it is not then so subject or
      subject the Company to any material tax in any such jurisdiction where it is
      not
      then so subject.

     

    (i)           Cooperate
      with the Holders to facilitate the timely preparation and delivery of
      certificates representing Registrable Securities to be sold pursuant to a
      Registration Statement, which certificates shall be free, to the extent
      permitted by applicable law and the Purchase Agreement, of all restrictive
      legends, and to enable such Registrable Securities to be in such denominations
      and registered in such names as any Holder may request at least two (2) Business
      Days prior to any sale of Registrable Securities. In connection therewith,
      the
      Company shall promptly after the effectiveness of the Registration Statement
      cause an opinion of counsel to be delivered to and maintained with its transfer
      agent, together with any other authorizations, certificates and directions
      required by the transfer agent, which authorize and direct the transfer agent
      to
      issue such Registrable Securities without legend upon sale by the Holder of
      such
      shares of Registrable Securities under the Registration Statement.

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

       

    

    (j)           Following
      the occurrence of any event contemplated by Section 3(c)(C)(iv), as promptly
      as
      possible, prepare a supplement or amendment, including a post-effective
      amendment, to the Registration Statement or a supplement to the related
      Prospectus or any document incorporated or deemed to be incorporated therein
      by
      reference, and file any other required document so that, as thereafter
      delivered, neither the Registration Statement nor such Prospectus will contain
      an untrue statement of a material fact or omit to state a material fact required
      to be stated therein or necessary to make the statements therein, in the light
      of the circumstances under which they were made, not misleading.

     

    (k)           Cause
      all Registrable Securities relating to such Registration Statement to be listed
      on any United States securities exchange, quotation system, market or
      over-the-counter bulletin board on which similar securities issued by the
      Company are then listed.

     

    (l)           Comply
      in all material respects with all applicable rules and regulations of the
      Commission and make generally available to its security holders earnings
      statements satisfying the provisions of Section 11(a) of the Securities Act
      and
      Rule 158 not later than 45 days after the end of any 3-month period (or 90
      days
      after the end of any 12-month period if such period is a fiscal year) commencing
      on the first day of the first fiscal quarter of the Company after the effective
      date of the Registration Statement, which statement shall conform to the
      requirements of Rule 158.

     

    (m)           The
      Company may require each selling Holder to furnish to the Company a certified
      statement as to the number of shares of Common Stock beneficially owned by
      such
      Holder and, if required by the Commission, the natural persons thereof that
      have
      voting and dispositive control over the shares. During any periods that the
      Company is unable to meet its obligations hereunder with respect to the
      registration of the Registrable Securities solely because any Holder fails
      to
      furnish such information within three Trading Days of the Company’s request, any
      liquidated damages that are accruing at such time as to such Holder only shall
      be tolled, and the Company may exclude from such registration the Registrable
      Securities of any such Holder who fails to furnish such information within
      a
      reasonable time prior to the filing of each Registration Statement, supplemented
      Prospectus and/or amended Registration Statement, until such information is
      delivered to the Company. Each Holder agrees to furnish to the Company a
      completed questionnaire in the form attached to this Agreement as Annex B (a “Selling
      Shareholder
      Questionnaire”) not less than two (2) Trading Days prior to the Filing
      Date or by the end of the fourth (4th)
      Trading Day following the date on which such Holder receives draft materials
      in
      accordance with this Section.

    

    If
      the
      Registration Statement refers to any Holder by name or otherwise as the holder
      of any securities of the Company, then such Holder shall have the right to
      require (if such reference to such Holder by name or otherwise is not required
      by the Securities Act or any similar federal statute then in force) the deletion
      of the reference to such Holder in any amendment or supplement to the
      Registration Statement filed or prepared subsequent to the time that such
      reference ceases to be required.

     

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

       

    

    Each
      Holder agrees by its acquisition of such Registrable Securities that, upon
      receipt of a notice from the Company of the occurrence of any event of the
      kind
      described in Section 3(c)(C)(i), 3(c)(C)(ii), 3(c)(C)(iii), 3(c)(C)(iv), or
      3(n), such Holder will forthwith discontinue disposition of such Registrable
      Securities under the Registration Statement until such Holder’s receipt of the
      copies of the supplemented Prospectus and/or amended Registration Statement
      contemplated by Section 3(j), or until it is advised in writing (the “Advice”) by the Company
      that
      the use of the applicable Prospectus may be resumed, and, in either case, has
      received copies of any additional or supplemental filings that are incorporated
      or deemed to be incorporated by reference in such Prospectus or Registration
      Statement; provided, that, notwithstanding the foregoing provisions of this
      Section 3(m), the Holders shall not be prohibited from selling Registrable
      Securities under the Registration Statement as a result of any event of the
      kind
      described in this Section 3(m) for more than an aggregate of 60 days in any
      12-month period.

     

    (n)           If
      (i) there is material non-public information regarding the Company which the
      Company’s Board of Directors (the “Board”) reasonably determines
      not to be in the Company’s best interest to disclose and which the Company is
      not otherwise required to disclose, or (ii) there is a significant business
      opportunity (including, but not limited to, the acquisition or disposition of
      assets (other than in the ordinary course of business) or any merger,
      consolidation, tender offer or other similar transaction) available to the
      Company which the Board reasonably determines not to be in the Company’s best
      interest to disclose and which the Company would be required to disclose under
      the Registration Statement, then the Company may (i) postpone or suspend filing
      or effectiveness of a registration statement or (ii) notify the Holders that
      the
      Registration Statement may not be used in connection with any sales of the
      Company’s securities, in each case, for a period not to exceed 30 consecutive
      days, provided that the Company may not postpone or suspend its obligation
      under
      this Section 3(n) for more than 60 days in the aggregate during any 12 month
      period (each, a “Blackout
      Period”).

     

    4.           Registration
      Expenses.

     

    All
      fees
      and expenses incident to the performance of or compliance with this Agreement
      by
      the Company shall be borne by the Company whether or not the Registration
      Statement is filed or becomes effective and whether or not any Registrable
      Securities are sold pursuant to the Registration Statement. The fees and
      expenses referred to in the foregoing sentence shall include, without
      limitation, (i) all registration and filing fees (including, without limitation,
      fees and expenses (A) with respect to filings required to be made with each
      securities exchange, quotation system, market or over-the-counter bulletin
      board
      on which Registrable Securities are required hereunder to be listed, (B) with
      respect to filings required to be made with the Commission, and (C) in
      compliance with state securities or Blue Sky laws (including, without
      limitation, reasonable and documented fees and disbursements of Special Counsel
      in connection with Blue Sky qualifications of the Registrable Securities and
      determination of the eligibility of the Registrable Securities for investment
      under the laws of such jurisdictions as the Holders of a majority of Registrable
      Securities may designate)), (ii) printing expenses (including, without
      limitation, expenses of printing certificates for Registrable Securities and
      of
      printing or photocopying prospectuses), (iii) messenger, telephone and delivery
      expenses, (iv) Securities Act liability insurance, if the Company so desires
      such insurance, (v) fees and expenses of all other Persons retained by the
      Company in connection with the consummation of the transactions contemplated
      by
      this Agreement, including, without limitation, the Company’s independent public
      accountants (including, in the case of an underwritten offering, the expenses
      of
      any comfort letters or costs associated with the delivery by independent public
      accountants of a comfort letter or comfort letters) and legal counsel, and
      (vi)
      reasonable and documented fees and expenses of the Special Counsel in connection
      with any Registration Statement hereunder. In addition, the Company shall be
      responsible for all of its internal expenses incurred in connection with the
      consummation of the transactions contemplated by this Agreement (including,
      without limitation, all salaries and expenses of its officers and employees
      performing legal or accounting duties), the expense of any annual audit, the
      fees and expenses incurred in connection with the listing of the Registrable
      Securities on any securities exchange as required hereunder.

     

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

       

    

    5.           Indemnification.

     

    (a)           Indemnification
      by the
      Company. The Company shall, notwithstanding any termination of this
      Agreement, indemnify and hold harmless each Holder, the officers, directors,
      agents, brokers (including brokers who offer and sell Registrable Securities
      as
      principal as a result of a pledge or any failure to perform under a margin
      call
      of Common Stock), investment advisors and employees of each of them, each Person
      who controls any such Holder (within the meaning of Section 15 of the Securities
      Act or Section 20 of the Exchange Act) and the officers, directors, agents
      and
      employees of each such controlling Person, to the fullest extent permitted
      by
      applicable law, from and against any and all losses, claims, damages,
      liabilities, costs (including, without limitation, costs of preparation and
      reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred,
      arising out of or relating to any untrue or alleged untrue statement of a
      material fact contained or incorporated by reference in the Registration
      Statement, any Prospectus or any form of prospectus or in any amendment or
      supplement thereto or in any preliminary prospectus, or arising out of or
      relating to any omission or alleged omission of a material fact required to
      be
      stated therein or necessary to make the statements therein (in the case of
      any
      Prospectus or form of prospectus or amendment or supplement thereto, in the
      light of the circumstances under which they were made) not misleading, except
      to
      the extent, but only to the extent, that (i) such untrue statements or omissions
      are based solely upon information regarding such Holder furnished in writing
      to
      the Company by such Holder expressly for use therein, which information was
      reasonably relied on by the Company for use therein or to the extent that such
      information relates to (x) such Holder and was reviewed and expressly approved
      in writing by such Holder expressly for use in the Registration Statement,
      such
      Prospectus or such form of prospectus or in any amendment or supplement thereto
      or (y) such Holder’s proposed method of distribution of Registrable Securities
      as set forth in Exhibit A (or as such
      Holder otherwise informs the Company in writing); or (ii) in the case of an
      occurrence of an event of the type described in Section 3(c)(C)(ii),
      3(c)(C)(iii), 3(c)(C)(iv) or 3(n), the use by a Holder of an outdated or
      defective Prospectus after the delivery to the Holder of written notice from
      the
      Company that the Prospectus is outdated or defective and prior to the receipt
      by
      such Holder of the Advice contemplated in Section 3(m); provided, however,
      that
      the indemnity agreement contained in this Section 5(a) shall not apply to
      amounts paid in settlement of any Losses if such settlement is effected without
      the prior written consent of the Company, which consent shall not be
      unreasonably withheld.  The Company shall notify the Holders promptly
      of the institution, threat or assertion of any Proceeding of which the Company
      is aware in connection with the transactions contemplated by this Agreement.
      Such indemnity shall remain in full force and effect regardless of any
      investigation made by or on behalf of an Indemnified Party (as defined in
      Section 5(c) to this Agreement) and shall survive the transfer of the
      Registrable Securities by the Holders.

     

    (b)           Indemnification
      by
      Holders. Each Holder shall, severally and not jointly, indemnify and hold
      harmless the Company, its directors, officers, agents and employees, each Person
      who controls the Company (within the meaning of Section 15 of the Securities
      Act
      and Section 20 of the Exchange Act), and the directors, officers, agents and
      employees of such controlling Persons, to the fullest extent permitted by
      applicable law, from and against all Losses, as incurred, arising solely out
      of
      or based solely upon any untrue statement of a material fact contained in the
      Registration Statement, any Prospectus, or any form of prospectus, or in any
      amendment or supplement thereto, or arising solely out of or based solely upon
      any omission of a material fact required to be stated therein or necessary
      to
      make the statements therein (in the case of any Prospectus or form of prospectus
      or supplement thereto, in the light of the circumstances under which they were
      made) not misleading, to the extent, but only to the extent, that (i) such
      untrue statement or omission is contained in or omitted from any information
      so
      furnished in writing by such Holder to the Company specifically for inclusion
      in
      the Registration Statement or such Prospectus and that such information was
      reasonably relied upon by the Company for use in the Registration Statement,
      such Prospectus, or in any amendment or supplement thereto, or to the extent
      that such information relates to (x) such Holder and was reviewed and expressly
      approved in writing by such Holder expressly for use in the Registration
      Statement, such Prospectus, or such form of prospectus or in any amendment
      or
      supplement thereto or (y) such Holder’s proposed method of distribution of
      Registrable Securities as set forth in Exhibit A (or as such
      Holder otherwise informs the Company in writing), (ii) in the case of an
      occurrence of an event of the type described in Section 3(c)(C)(ii),
      3(c)(C)(iii), 3(c)(C)(iv) or 3(n), the use by a Holder of an outdated or
      defective Prospectus after the delivery to the Holder of written notice from
      the
      Company that the Prospectus is outdated or defective and prior to the receipt
      by
      such Holder of the Advice contemplated in Section 3(m) or (iii) such Holder’s
      failure to comply with the Prospectus delivery requirements of the Securities
      Act through no fault of the Company; provided, however, that the indemnity
      agreement contained in this Section 5(b) shall not apply to amounts paid in
      settlement of any Losses if such settlement is effected without the prior
      written consent of the Holder, which consent shall not be unreasonably withheld.
      Notwithstanding anything to the contrary contained herein, the Holder shall
      be
      liable under this Section 5(b) for only that amount as does not exceed the
      net
      proceeds to such Holder as a result of the sale of Registrable Securities
      pursuant to such Registration Statement.

     

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

       

    

    (c)           Conduct
      of Indemnification
      Proceedings. If any Proceeding shall be brought or asserted against any
      Person entitled to indemnity hereunder (an “Indemnified Party”), such
      Indemnified Party promptly shall notify the Person from whom indemnity is sought
      (the “Indemnifying
      Party”) in writing, and the Indemnifying Party shall have the right to
      assume the defense thereof, including the employment of counsel reasonably
      satisfactory to the Indemnified Party and the payment of all reasonable fees
      and
      expenses incurred in connection with defense thereof; provided, that the failure
      of any Indemnified Party to give such notice shall not relieve the Indemnifying
      Party of its obligations or liabilities pursuant to this Agreement, except
      (and
      only) to the extent that it shall be finally determined by a court of competent
      jurisdiction (which determination is not subject to appeal or further review)
      that such failure shall have proximately and materially adversely prejudiced
      the
      Indemnifying Party.

     

    An
      Indemnified Party shall have the right to employ separate counsel in any such
      Proceeding and to participate in the defense thereof, but the fees and expenses
      of such counsel shall be at the expense of such Indemnified Party or Parties
      unless: (1) the Indemnifying Party has agreed in writing to pay such fees and
      expenses; or (2) the Indemnifying Party shall have failed promptly to assume
      the
      defense of such Proceeding and to employ counsel reasonably satisfactory to
      such
      Indemnified Party in any such Proceeding; or (3) the named parties to any such
      Proceeding (including any impleaded parties) include both such Indemnified
      Party
      and the Indemnifying Party, and such Indemnified Party shall have been advised
      in writing by counsel that a conflict of interest is likely to exist if the
      same
      counsel were to represent such Indemnified Party and the Indemnifying Party
      (in
      which case, if such Indemnified Party notifies the Indemnifying Party in writing
      that it elects to employ separate counsel at the expense of the Indemnifying
      Party, the Indemnifying Party shall not have the right to assume the defense
      thereof and such counsel shall be at the reasonable expense of the Indemnifying
      Party). The Indemnifying Party shall not be liable for any settlement of any
      such Proceeding effected without its written consent, which consent shall not
      be
      unreasonably withheld. No Indemnifying Party shall, without the prior written
      consent of the Indemnified Party, effect any settlement of any pending
      Proceeding in respect of which any Indemnified Party is a party, unless such
      settlement includes an unconditional release of such Indemnified Party from
      all
      liability on claims that are the subject matter of such Proceeding and does
      not
      impose any monetary or other obligation or restriction on the Indemnified
      Party.

     

    All
      reasonable fees and expenses of the Indemnified Party (including reasonable
      fees
      and expenses to the extent incurred in connection with investigating or
      preparing to defend such Proceeding in a manner not inconsistent with this
      Section) shall be paid to the Indemnified Party, as incurred, within ten (10)
      Business Days of written notice thereof to the Indemnifying Party, which notice
      shall be delivered no more frequently than on a monthly basis (regardless of
      whether it is ultimately determined that an Indemnified Party is not entitled
      to
      indemnification hereunder; provided, that the Indemnifying Party may require
      such Indemnified Party to undertake to reimburse all such fees and expenses
      to
      the extent it is finally judicially determined that such Indemnified Party
      is
      not entitled to indemnification hereunder).

     

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

       

    

    (d)           Contribution.
      If a
      claim for indemnification under Section 5(a) or 5(b) is unavailable to an
      Indemnified Party because of a failure or refusal of a governmental authority
      to
      enforce such indemnification in accordance with its terms (by reason of public
      policy or otherwise), then each Indemnifying Party, in lieu of indemnifying
      such
      Indemnified Party, shall contribute to the amount paid or payable by such
      Indemnified Party as a result of such Losses, in such proportion as is
      appropriate to reflect the relative fault of the Indemnifying Party and
      Indemnified Party in connection with the actions, statements or omissions that
      resulted in such Losses as well as any other relevant equitable considerations.
      The relative fault of such Indemnifying Party and Indemnified Party shall be
      determined by reference to, among other things, whether any action in question,
      including any untrue or alleged untrue statement of a material fact or omission
      or alleged omission of a material fact, has been taken or made by, or relates
      to
      information supplied by, such Indemnifying Party or Indemnified Party, and
      the
      parties’ relative intent, knowledge, access to information and opportunity to
      correct or prevent such action, statement or omission. The amount paid or
      payable by a party as a result of any Losses shall be deemed to include, subject
      to the limitations set forth in Section 5(c), any reasonable attorneys’ or other
      reasonable fees or expenses incurred by such party in connection with any
      Proceeding to the extent such party would have been indemnified for such fees
      or
      expenses if the indemnification provided for in this Section was available
      to
      such party in accordance with its terms. Notwithstanding anything to the
      contrary contained herein, the Holder shall be required to contribute under
      this
      Section 5(d) for only that amount as does not exceed the net proceeds to such
      Holder as a result of the sale of Registrable Securities pursuant to such
      Registration Statement.

     

    The
      parties hereto agree that it would not be just and equitable if contribution
      pursuant to this Section 5(d) were determined by pro rata allocation or by
      any
      other method of allocation that does not take into account the equitable
      considerations referred to in the immediately preceding paragraph. No Person
      guilty of fraudulent misrepresentation (within the meaning of Section 11(f)
      of
      the Securities Act) shall be entitled to contribution from any Person who was
      not guilty of such fraudulent misrepresentation.

     

    The
      indemnity and contribution agreements contained in this Section are in addition
      to any liability that the Indemnifying Parties may have to the Indemnified
      Parties. The indemnity and contribution agreements herein are in addition to
      and
      not in diminution or limitation of any indemnification provisions under the
      Purchase Agreement.

     

    6.           Rule
      144.

     

    As
      long
      as any Holder owns Purchased Shares, Conversion Shares, Warrants or Warrant
      Shares, the Company covenants to timely file (or obtain extensions in respect
      thereof and file within the applicable grace period) all reports required to
      be
      filed by the Company after the date hereof pursuant to Section 13(a) or 15(d)
      of
      the Exchange Act. As long as any Holder owns Purchased Shares, Conversion
      Shares, Warrants or Warrant Shares, if the Company is not required to file
      reports pursuant to Section 13(a) or 15(d) of the Exchange Act, it will prepare
      and furnish to the Holders and make publicly available in accordance with Rule
      144(c) promulgated under the Securities Act annual and quarterly financial
      statements, together with a discussion and analysis of such financial statements
      in form and substance substantially similar to those that would otherwise be
      required to be included in reports required by Section 13(a) or 15(d) of the
      Exchange Act, as well as any other information required thereby, in the time
      period that such filings would have been required to have been made under the
      Exchange Act. The Company further covenants that it will take such further
      action as any Holder may reasonably request, all to the extent required from
      time to time to enable such Person to sell Purchased Shares, Conversion Shares,
      Warrants and Warrant Shares without registration under the Securities Act within
      the limitation of the exemptions provided by Rule 144 promulgated under the
      Securities Act, including compliance with the provisions of the Purchase
      Agreement relating to the transfer of the Purchased Shares, Conversion Shares,
      Warrants and Warrant Shares. Upon the request of any Holder, the Company shall
      deliver to such Holder a written certification of a duly authorized officer
      as
      to whether it has complied with such requirements.

     

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

       

    

    7.           Miscellaneous.

     

    (a)           Remedies.
      In the
      event of a breach by the Company or by a Holder, of any of their obligations
      under this Agreement, each Holder or the Company, as the case may be, in
      addition to being entitled to exercise all rights granted by law and under
      this
      Agreement, including recovery of damages, will be entitled to specific
      performance of its rights under this Agreement. The Company and each Holder
      agree that monetary damages would not provide adequate compensation for any
      losses incurred by reason of a breach by it of any of the provisions of this
      Agreement and hereby further agrees that, in the event of any action for
      specific performance in respect of such breach, it shall waive the defense
      that
      a remedy at law would be adequate.

     

    (b)           No
      Inconsistent
      Agreements. Except as otherwise disclosed in the Purchase Agreement,
      neither the Company nor any of its subsidiaries is a party to an agreement
      currently in effect, nor shall the Company or any of its subsidiaries, on or
      after the date of this Agreement, enter into any agreement with respect to
      its
      securities that is inconsistent with the rights granted to the Holders in this
      Agreement or otherwise conflicts with the provisions hereof. Without limiting
      the generality of the foregoing, other than with respect to the rights of the
      holders of the Company’s currently outstanding warrants and convertible notes
      and the common stock underlying such warrants and convertible notes, without
      the
      written consent of the Holders of a majority of the then outstanding Registrable
      Securities, the Company shall not grant to any Person the right to request
      the
      Company to register any securities of the Company under the Securities Act
      unless the rights so granted are subject in all respects to the rights of the
      Holders set forth herein, and are not otherwise in conflict with the provisions
      of this Agreement.

     

    (c)           Notice
      of
      Effectiveness. Within two (2) Business Days after the Registration
      Statement which includes the Registrable Securities is ordered effective by
      the
      Commission, the Company shall deliver, and shall cause legal counsel for the
      Company to deliver, to the transfer agent for such Registrable Securities (with
      copies to the Holders whose Registrable Securities are included in such
      Registration Statement) confirmation that the Registration Statement has been
      declared effective by the Commission in the form attached hereto as Exhibit
      B.

     

    (d)           Piggy-Back
      Registrations. If at any time when there is not an effective Registration
      Statement covering all of the Registrable Securities, the Company shall
      determine to prepare and file with the Commission a registration statement
      relating to an offering for its own account or the account of others under
      the
      Securities Act of any of its equity securities, other than on Form S-4 or Form
      S-8 (each as promulgated under the Securities Act) or their then equivalents
      relating to equity securities to be issued solely in connection with any
      acquisition of any entity or business or equity securities issuable in
      connection with stock option or other employee benefit plans and other than
      with
      respect to the rights of the holders of the Company’s currently outstanding
      warrants and convertible notes and the common stock underlying such warrants
      and
      convertible notes, the Company shall send to each Holder of Registrable
      Securities written notice of such determination and, if within seven (7)
      Business Days after receipt of such notice, any such Holder shall so request
      in
      writing (which request shall specify the Registrable Securities intended to
      be
      disposed of by the Holder), the Company will cause the registration under the
      Securities Act of all Registrable Securities which the Company has been so
      requested to register by the Holder, to the extent required to permit the
      disposition of the Registrable Securities so to be registered, provided that
      if
      at any time after giving written notice of its intention to register any
      securities and prior to the effective date of the registration statement filed
      in connection with such registration, the Company shall determine for any reason
      not to register or to delay registration of such securities, the Company may,
      at
      its election, give written notice of such determination to such Holder and,
      thereupon, (i) in the case of a determination not to register, shall be relieved
      of its obligation to register any Registrable Securities in connection with
      such
      registration (but not from its obligation to pay expenses in accordance with
      Section 4 hereof), and (ii) in the case of a determination to delay registering,
      shall be permitted to delay registering any Registrable Securities being
      registered pursuant to this Section 7(d) for the same period as the delay in
      registering such other securities. The Company shall include in such
      registration statement all or any part of such Registrable Securities such
      Holder requests to be registered. In the case of an underwritten public
      offering, if the managing underwriter(s) or underwriter(s) should reasonably
      object to the inclusion of the Registrable Securities in such registration
      statement, then if the Company after consultation with the managing underwriter
      should reasonably determine that the inclusion of such Registrable Securities,
      would materially adversely affect the offering contemplated in such registration
      statement, and based on such determination recommends inclusion in such
      registration statement of fewer or none of the Registrable Securities of the
      Holders, then (x) the number of Registrable Securities of the Holders included
      in such registration statement shall be reduced pro-rata among such Holders
      (based upon the number of Registrable Securities requested to be included in
      the
      registration), if the Company after consultation with the underwriter(s)
      recommends the inclusion of fewer Registrable Securities, or (y) none of the
      Registrable Securities of the Holders shall be included in such registration
      statement, if the Company after consultation with the underwriter(s) recommends
      the inclusion of none of such Registrable Securities; provided, however, that
      if
      securities are being offered for the account of other persons or entities as
      well as the Company, such reduction shall not represent a greater fraction
      of
      the number of Registrable Securities intended to be offered by the Holders
      than
      the fraction of similar reductions imposed on such other persons or entities
      (other than the Company).

     

    
      
        
        

      

      
        14

        
          

        

      

      
        
        

      

       

    

    (e)           Failure
      to File Registration
      Statement; Failure to Become Effective and Other Events. The Company and
      the Holders agree that the Holders will suffer damages if the Registration
      Statement is not filed on or prior to the Filing Date and maintained in the
      manner contemplated herein during the Effectiveness Period. The Company and
      the
      Holders further agree that it would not be feasible to ascertain the extent
      of
      such damages with precision. Accordingly, if (i) the Registration Statement
      is
      not filed on or prior to the Filing Date, or (ii) the Company fails to file
      with
      the Commission a request for acceleration in accordance with Rule 461
      promulgated under the Securities Act within five (5) Business Days of the date
      that the Company is notified (orally or in writing, whichever is earlier) by
      the
      Commission that a Registration Statement will not be “reviewed,” or not subject
      to further review, or (iii) a Registration Statement registering for resale
      all
      of the Initial Shares is not declared effective by the Commission by the
      Effectiveness Date of the Initial Registration Statement with the aggregate
      number of such Initial Shares divided among all Holders on a pro-rata basis
      based on their purchase of the Securities pursuant to the Purchase Agreement,
      or
      (iv) all of the Registrable Securities are not registered for resale pursuant
      to
      one or more effective Registration Statements on or before October 30, 2008,
      or
      (v) the Registration Statement is filed with and declared effective by the
      Commission but thereafter ceases to be effective as to all applicable
      Registrable Securities at any time prior to the expiration of the Effectiveness
      Period, without being succeeded immediately by a subsequent Registration
      Statement filed with the Commission, except as otherwise permitted by this
      Agreement, including pursuant to Section 3(n), or (vi) trading in the Common
      Stock shall be suspended or if the Common Stock is delisted from each securities
      exchange, quotation system, market or over-the-counter bulletin board on which
      Registrable Securities are required hereunder to be listed (each an “Exchange”), without
      immediately being listed on any other Exchange, for any reason for more than
      five (5) Business Days, other than pursuant to Section 3(n), or (vii) the
      Company refuses or fails to effect any exercise of Warrants into Warrant Shares
      in accordance with the terms of the Warrants for any reason without the consent
      of the particular Holder (any such failure or breach being referred to as an
      “Event”), the Company
      shall, as the remedy for same, pay in cash as liquidated damages for such
      failure and not as a penalty to each Holder an amount equal to one percent
      (1%)
      of such Holder’s Subscription Amount for the initial thirty (30) day period
      until the applicable Event has been cured, which shall be pro rated for such
      periods less than thirty (30) days and one percent (1%) of such Holder’s
      Subscription Amount for each subsequent thirty (30) day period until the
      applicable Event has been cured which shall be pro rated for such periods less
      than thirty days (the “Periodic Amount”). Payments
      to be made pursuant to this Section 7(e) shall be due and payable immediately
      upon demand in immediately available cash funds. The parties agree that the
      Periodic Amount represents a reasonable estimate on the part of the parties,
      as
      of the date of this Agreement, of the amount of damages that may be incurred
      by
      the Holders if the Registration Statement is not filed on or prior to the Filing
      Date and maintained in the manner contemplated herein during the Effectiveness
      Period or if any other Event as described herein has occurred. The parties
      further agree that the maximum aggregate liquidated damages payable to a Holder
      under this Section 7(e) shall be 10% of the aggregate Subscription Amount paid
      by such Holder pursuant to the Purchase Agreement.  Notwithstanding
      the foregoing, the Company shall remain obligated to cure the breach or correct
      the condition that caused the Event, and the Holder shall have the right to
      take
      any action necessary or desirable to enforce such obligation.  Each
      Holder of Registrable Securities acknowledges that, notwithstanding any
      provision of this Agreement, no damages shall be payable in connection with
      the
      Company’s imposition of a Blackout Period in accordance with Section 3(n) of
      this Agreement.

     

    
      
        
        

      

      
        15

        
          

        

      

      
        
        

      

       

    

    (f)           Specific
      Enforcement,
      Consent to Jurisdiction.

     

    (i)           The
      Company and the Holders acknowledge and agree that irreparable damage would
      occur in the event that any of the provisions of this Agreement were not
      performed in accordance with their specific terms or were otherwise breached.
      It
      is accordingly agreed that the parties shall be entitled to an injunction or
      injunctions to prevent or cure breaches of the provisions of this Agreement
      and
      to enforce specifically the terms and provisions hereof, this being in addition
      to any other remedy to which any of them may be entitled by law or
      equity.

     

    (ii)           Each
      of the Company and the Holders (i) hereby irrevocably submits to the exclusive
      jurisdiction of the state and federal courts located in New York City, New
      York
      for the purposes of any suit, action or proceeding arising out of or relating
      to
      this Agreement and (ii) hereby waives, and agrees not to assert in any such
      suit, action or proceeding, any claim that it is not personally subject to
      the
      jurisdiction of such court, that the suit, action or proceeding is brought
      in an
      inconvenient forum or that the venue of the suit, action or proceeding is
      improper. Each of the Company and the Holders consents to process being served
      in any such suit, action or proceeding by mailing a copy thereof to such party
      at the address in effect for notices to it under this Agreement and agrees
      that
      such service shall constitute good and sufficient service of process and notice
      thereof. Nothing in this Section 7(f) shall affect or limit any right to serve
      process in any other manner permitted by law.

     

    (g)           Amendments
      and
      Waivers. The provisions of this Agreement, including the provisions of
      this sentence, may not be amended, modified or supplemented, and waivers or
      consents to departures from the provisions hereof may not be given, unless
      the
      same shall be in writing and signed by the Company and the Holders of at least
      66% or more of the Registrable Securities (including, for this purpose, any
      Registrable Securities issuable upon conversion or exercise (as applicable)
      of
      any Preferred Stock or Warrant). If a Registration Statement does not register
      all of the Registrable Securities pursuant to a waiver or amendment done in
      compliance with the previous sentence, then the number of Registrable Securities
      to be registered for each Holder shall be reduced pro rata among all Holders
      and
      each Holder shall have the right to designate which of its Registrable
      Securities shall be omitted from such Registration Statement. Notwithstanding
      the foregoing, a waiver or consent to depart from the provisions hereof with
      respect to a matter that relates exclusively to the rights of Holders and that
      does not directly or indirectly affect the rights of other Holders may be given
      by Holders of the Registrable Securities to which such waiver or consent
      relates; provided, however, that the provisions of this sentence may not be
      amended, modified, or supplemented except in accordance with the provisions
      of
      the immediately preceding sentence.  Notwithstanding the foregoing,
      this Agreement may be amended by the Company with the consent of SCO Capital
      Partners LLC and without the consent of the other Purchasers by supplementing
      Schedule 1 with
      respect to Purchasers in any Additional Closing pursuant to Section 2.1 of
      the
      Purchase Agreement and by adding any such Purchaser as a party to this
      Agreement, provided that any such Purchaser agrees to be bound by this Agreement
      by executing a counterpart signature page to this Agreement.

     

    
      
        
        

      

      
        16

        
          

        

      

      
        
        

      

       

    

    (h)           Notices.
      Any and all
      notices or other communications or deliveries required or permitted to be
      provided hereunder shall be in writing and shall be deemed given and effective
      on the earlier of (i) the date of transmission, if such notice or communication
      is delivered via facsimile at the facsimile telephone number specified for
      notice prior to 5:00 p.m., New York City time, on a Business Day, (ii) the
      next
      Business Day after the date of transmission, if such notice or communication
      is
      delivered via facsimile at the facsimile number specified in this Section on
      a
      day that is not a Business Day or later than 5:00 p.m., New York City time,
      on
      any date and earlier than 11:59 p.m., New York City time, on such date, (iii)
      the Business Day following the date of mailing, if sent by nationally recognized
      overnight courier service such as Federal Express or (iv) actual receipt by
      the
      party to whom such notice is required to be given. The addresses for such
      communications shall be with respect to each Holder at its address set forth
      under its name on Schedule 1 attached
      hereto, or with respect to the Company, addressed to:

     

    Access
      Pharmaceuticals, Inc.

    2600
      Stemmons Freeway, Suite 176

    Dallas,
      Texas 75207

    Attention:
      President

    Facsimile
      No.: (214) 905-5101

    

    or
      to
      such other address or addresses or facsimile number or numbers as any such
      party
      may most recently have designated in writing to the other parties hereto by
      such
      notice. Copies of notices to the Company shall be sent to:

     

    Bingham
      McCutchen LLP

    150
      Federal Street

    Boston,
      Massachusetts 02110

    Attention:  John
      J. Concannon, III

    Facsimile
      No.: (617) 951-8736

    

    Copies
      of
      notices to any Holder shall be sent to the addresses, if any, listed on Schedule 1 attached
      hereto.

     

    (i)           Successors
      and
      Assigns. This Agreement shall be binding upon and inure to the benefit of
      the parties and their successors and permitted assigns and shall inure to the
      benefit of each Holder and its successors and assigns; provided, that the
      Company may not assign this Agreement or any of its rights or obligations
      hereunder without the prior written consent of each Holder; and provided,
      further, that each Holder may assign its rights hereunder in the manner and
      to
      the Persons as permitted under the Purchase Agreement.

     

    
      
        
        

      

      
        17

        
          

        

      

      
        
        

      

       

    

    (j)           Assignment
      of Registration
      Rights. The rights of each Holder hereunder, including the right to have
      the Company register for resale Registrable Securities in accordance with the
      terms of this Agreement, shall be automatically assignable by each Holder to
      any
      transferee of such Holder of all or a portion of the Purchased Shares, the
      Warrants, the Warrant Shares or the Registrable Securities if: (i) the Holder
      agrees in writing with the transferee or assignee to assign such rights, and
      a
      copy of such agreement is furnished to the Company within a reasonable time
      after such assignment, (ii) the Company is, within a reasonable time after
      such
      transfer or assignment, furnished with written notice of (a) the name and
      address of such transferee or assignee, and (b) the securities with respect
      to
      which such registration rights are being transferred or assigned, (iii)
      following such transfer or assignment the further disposition of such securities
      by the transferee or assignees is restricted under the Securities Act and
      applicable state securities laws, (iv) at or before the time the Company
      receives the written notice contemplated by clause (ii) of this Section 7(j),
      the transferee or assignee agrees in writing with the Company to be bound by
      all
      of the provisions of this Agreement, and (v) such transfer shall have been
      made
      in accordance with the applicable requirements of the Purchase Agreement. The
      rights to assignment shall apply to the Holders (and to subsequent) successors
      and assigns.

     

    The
      Company may require, as a condition of allowing such assignment in connection
      with a transfer of Purchased Shares, Warrants, Warrant Shares or Registrable
      Securities (i) that the Holder or transferee of all or a portion of the
      Purchased Shares, the Warrants, the Warrant Shares or the Registrable Securities
      as the case may be, furnish to the Company a written opinion of counsel that
      is
      reasonably acceptable to the Company to the effect that such transfer may be
      made without registration under the Securities Act, (ii) that the Holder or
      transferee execute and deliver to the Company an investment letter in form
      and
      substance acceptable to the Company and (iii) that the transferee be an
“accredited investor” as defined in Rule 501(a) promulgated under the Securities
      Act.

     

    (k)           Counterparts;
      Facsimile. This Agreement may be executed in any number of counterparts,
      each of which when so executed shall be deemed to be an original and, all of
      which taken together shall constitute one and the same Agreement. In the event
      that any signature is delivered by electronic means or facsimile transmission,
      such signature shall create a valid binding obligation of the party executing
      (or on whose behalf such signature is executed) the same with the same force
      and
      effect as if such facsimile signature were the original thereof.

     

    (l)           Governing
      Law. This
      Agreement shall be governed by and construed in accordance with the laws of
      the
      State of New York, without regard to principles of conflicts of law
      thereof.

     

    (m)           Cumulative
      Remedies.
      Unless otherwise provided herein, the remedies provided herein are cumulative
      and not exclusive of any remedies provided by law.

     

    (n)           Severability.
      If any
      term, provision, covenant or restriction of this Agreement is held by a court
      of
      competent jurisdiction to be invalid, illegal, void or unenforceable in any
      respect, the remainder of the terms, provisions, covenants and restrictions
      set
      forth herein shall remain in full force and effect and shall in no way be
      affected, impaired or invalidated, and the parties hereto shall use their
      reasonable efforts to find and employ an alternative means to achieve the same
      or substantially the same result as that contemplated by such term, provision,
      covenant or restriction. It is hereby stipulated and declared to be the
      intention of the parties that they would have executed the remaining terms,
      provisions, covenants and restrictions without including any of such that may
      be
      hereafter declared invalid, illegal, void or unenforceable.

     

    (o)           Headings.
      The
      headings herein are for convenience only, do not constitute a part of this
      Agreement and shall not be deemed to limit or affect any of the provisions
      hereof.

     

    (p)           Obligations
      of
      Purchasers. The Company acknowledges that the obligations of each
      Purchaser under this Agreement, are several and not joint with the obligations
      of any other Purchaser, and no Purchaser shall be responsible in any way for
      the
      performance of the obligations of any other Purchaser under this
      Agreement.  The decision of each Purchaser to enter into to this
      Agreement has been made by such Purchaser independently of any other
      Purchaser.  The Company further acknowledges that nothing contained in
      this Agreement, and no action taken by any Purchaser pursuant hereto, shall
      be
      deemed to constitute the Purchasers as a partnership, an association, a joint
      venture or any other kind of entity, or create a presumption that the Purchasers
      are in any way acting in concert or as a group with respect to such obligations
      or the transactions contemplated hereby.  Each Purchaser shall be
      entitled to independently protect and enforce its rights, including without
      limitation, the rights arising out of this Agreement, and it shall not be
      necessary for any other Purchaser to be joined as an additional party in any
      proceeding for such purpose.

     

    
      
        
        

      

      
        18

        
          

        

      

      
        
        

      

       

    

      Each
      Purchaser has been represented by its own separate legal counsel in their review
      and negotiation of this Agreement and with respect to the transactions
      contemplated hereby. For reasons of administrative convenience only, this
      Agreement has been prepared by Special Counsel (counsel for SCO Capital Partners
      LLC) and the Special Counsel will perform certain duties under this Agreement.
      Such counsel does not represent all of the Purchasers but only SCO Capital
      Partners LLC. The Company has elected to provide all Purchasers with the same
      terms and Agreement for the convenience of the Company and not because it was
      required or requested to do so by the Purchasers.  The Company
      acknowledges that such procedure with respect to this Agreement in no way
      creates a presumption that the Purchasers are in any way acting in concert
      or as
      a group with respect to this Agreement or the transactions contemplated hereby
      or thereby.

     

    (q)           No
      Other Shares on
      Registrations; Prohibition on Filing Other Registration Statements.
      Neither the Company nor any of its security holders (other than the Holders
      in
      such capacity pursuant hereto) may include securities of the Company in any
      Registration Statements other than the Registrable Securities.  The
      Company shall not file any other registration statements until all Registrable
      Securities are registered pursuant to a Registration Statement that is declared
      effective by the Commission, provided that this Section 7(q) shall not prohibit
      the Company from filing amendments to registration statements filed prior to
      the
      date of this Agreement.

    

     

    [signature
      page follows]

     

    

     

    

     

    

     

    
      
         
          

      

      
        19

        
          

        

      

      
         
          

      

    

    IN
      WITNESS WHEREOF, the parties hereto have caused this Amended and Restated
      Investor Rights Agreement to be duly executed by their respective authorized
      persons as of the date first indicated above.

     

    COMPANY:

    

    ACCESS
      PHARMACEUTICALS, INC.

    

    

    By:
      /s/ Stephen B.
      Thompson                                                                           

    Name:
      Stephen B. Thompson

    Title:
      Vice President, Chief Financial Officer

    

    

    

    

    

    

    
      
        
        

      

      
        20

        
          

        

      

      
        
        

      

    

    

    

    

     

    

    

    

    PURCHASERS:

    

    Print
      Exact Name: 

    

    

     

    Name:
      

    Title:
      

    

    

    

     

    

    

    

    

    

    [Omnibus
      Access Pharmaceuticals, Inc. Amended and Restated

    Investor
      Rights Agreement (2008) Signature Page]

    

    
      
         
          

      

      
        21

        
          

        

      

      
         
          

      

    

    EXHIBIT
      A

    

    PLAN
      OF
      DISTRIBUTION

    

    

    We
      are
      registering the shares of common stock on behalf of the selling security
      holders. Sales of shares may be made by selling security holders, including
      their respective donees, transferees, pledgees or other successors-in-interest
      directly to purchasers or to or through underwriters, broker-dealers or through
      agents. Sales may be made from time to time on the ________________, any other
      exchange or market upon which our shares may trade in the future, in the
      over-the-counter market or otherwise, at market prices prevailing at the time
      of
      sale, at prices related to market prices, or at negotiated or fixed prices.
      The
      shares may be sold by one or more of, or a combination of, the
      following:

     

    
      	
              -

            	
              a
                block trade in which the broker-dealer so engaged will attempt to
                sell the
                shares as agent but may position and resell a portion of the block
                as
                principal to facilitate the transaction (including crosses in which
                the
                same broker acts as agent for both sides of the
                transaction);

            

    

     

    
      	
              -

            	
              purchases
                by a broker-dealer as principal and resale by such broker-dealer,
                including resales for its account, pursuant to this
                prospectus;

            

    

     

    
      	
              -

            	
              ordinary
                brokerage transactions and transactions in which the broker solicits
                purchases;

            

    

     

    
      	
              -

            	
              through
                options, swaps or derivatives;

            

    

     

    
      	
              -

            	
              in
                privately negotiated transactions;

            

    

     

    
      	
              -

            	
              in
                making short sales or in transactions to cover short
                sales;

            

    

     

    -           put
      or call option transactions relating to the shares;

     

    -           through
      the writing or settlement of options or other hedging transactions, whether
      through an options exchange or otherwise;

     

    -           a
      combination of any such methods of sale; or

     

    -           any
      other method permitted pursuant to applicable law.

     

    The
      selling security holders may effect these transactions by selling shares
      directly to purchasers or to or through broker-dealers, which may act as agents
      or principals. These broker-dealers may receive compensation in the form of
      discounts, concessions or commissions from the selling security holders and/or
      the purchasers of shares for whom such broker-dealers may act as agents or
      to
      whom they sell as principals, or both (which compensation as to a particular
      broker-dealer might be in excess of customary commissions). The selling security
      holders have advised us that they have not entered into any agreements,
      understandings or arrangements with any underwriters or broker-dealers regarding
      the sale of their securities.

     

    
      
        
        

      

      
        22

        
          

        

      

      
        
        

      

       

    

    The
      selling security holders may enter into hedging transactions with broker-dealers
      or other financial institutions. In connection with those transactions, the
      broker-dealers or other financial institutions may engage in short sales of
      the
      shares or of securities convertible into or exchangeable for the shares in
      the
      course of hedging positions they assume with the selling security holders.
      The
      selling security holders may also enter into options or other transactions
      with
      broker-dealers or other financial institutions which require the delivery of
      shares offered by this prospectus to those broker-dealers or other financial
      institutions. The broker-dealer or other financial institution may then resell
      the shares pursuant to this prospectus (as amended or supplemented, if required
      by applicable law, to reflect those transactions).

     

    The
      selling security holders and any broker-dealers that act in connection with
      the
      sale of shares may be deemed to be “underwriters” within the meaning of Section
      2(11) of the Securities Act of 1933, and any commissions received by
      broker-dealers or any profit on the resale of the shares sold by them while
      acting as principals may be deemed to be underwriting discounts or commissions
      under the Securities Act. The selling security holders may agree to indemnify
      any agent, dealer or broker-dealer that participates in transactions involving
      sales of the shares against liabilities, including liabilities arising under
      the
      Securities Act. We have agreed to indemnify each of the selling security holders
      and each selling security holder has agreed, severally and not jointly, to
      indemnify us against some liabilities in connection with the offering of the
      shares, including liabilities arising under the Securities Act.

     

    The
      selling security holders will be subject to the prospectus delivery requirements
      of the Securities Act. We have informed the selling security holders that the
      anti-manipulative provisions of Regulation M promulgated under the Securities
      Exchange Act of 1934 may apply to their sales in the market.

     

    Selling
      security holders also may resell all or a portion of the shares in open market
      transactions in reliance upon Rule 144 under the Securities Act, provided they
      meet the criteria and conform to the requirements of Rule 144.

     

    Upon
      being notified by a selling security holder that a material arrangement has
      been
      entered into with a broker-dealer for the sale of shares through a block trade,
      special offering, exchange distribution or secondary distribution or a purchase
      by a broker or dealer, we will file a supplement to this prospectus, if required
      pursuant to Rule 424(b) under the Securities Act, disclosing:

     

    
      	
              -

            	
              the
                name of each such selling security holder and of the participating
                broker-dealer(s);

            

    

     

    
      	
              -

            	
              the
                number of shares involved;

            

    

     

    
      	
              -

            	
              the
                initial price at which the shares were
                sold;

            

    

     

    
      	
              -

            	
              the
                commissions paid or discounts or concessions allowed to the
                broker-dealer(s), where applicable;

            

    

     

    
      	
              -

            	
              that
                such broker-dealer(s) did not conduct any investigation to verify
                the
                information set out or incorporated by reference in this prospectus;
                and

            

    

     

    
      	
              -

            	
              other
                facts material to the transactions.

            

    

     

    
      
        
        

      

      
        23

        
          

        

      

      
        
        

      

       

    

    In
      addition, if required under applicable law or the rules or regulations of the
      Commission, we will file a supplement to this prospectus when a selling security
      holder notifies us that a donee or pledgee intends to sell more than 500 shares
      of common stock.

     

    We
      are
      paying all expenses and fees customarily paid by the issuer in connection with
      the registration of the shares. The selling security holders will bear all
      brokerage or underwriting discounts or commissions paid to broker-dealers in
      connection with the sale of the shares.

     

    
      
         
          

      

      
        24

        
          

        

      

      
         
          

      

    

    

    EXHIBIT
      B

     

    FORM
      OF
      NOTICE OF EFFECTIVENESS OF REGISTRATION STATEMENT

     

    

    [Name
      and
      Address of Transfer Agent]

    

    Re:  Access
      Pharmaceuticals, Inc.

    

    Dear
      [______]:

    

    We
      are
      counsel to Access Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and have
      represented the Company in connection with that certain Amended and
      Restated

     

    Preferred
      Stock and Warrant Purchase Agreement (the “Purchase Agreement”) dated as
      of __________________, 2007 by and among the Company and the buyers named
      therein (collectively, the “Holders”) pursuant to which
      the Company issued to the Holders its Series A convertible preferred stock
      (the
“PreferredStock”)
      convertible into
      shares of its Common Stock, par value $0.01 per share (the “Common Stock”), and warrants
      to purchase shares of the Common Stock (the “Warrants”). Pursuant to the
      Purchase Agreement, the Company has also entered into an Amended and Restated
      Investor Rights Agreement with the Holders (the “Investor Rights Agreement”)
      pursuant to which the Company agreed, among other things, to register the shares
      of Common Stock issuable upon conversion of the Preferred Stock, in payment
      of
      dividends on the Preferred stock and upon exercise of the Warrants, under the
      Securities Act of 1933, as amended (the “1933 Act”). In connection with the
      Company’s obligations under the Investor Rights Agreement, on ____________ ___,
      2006, the Company filed a Registration Statement on Form S-__ (File No.
      333-_____________) (the “Registration Statement”) with the Securities and
      Exchange Commission (the “SEC”) relating to the
      Registrable Securities which names each of the Holders as a selling
      securityholder thereunder.

     

    In
      connection with the foregoing, we advise you that a member of the SEC’s staff
      has advised us by telephone that the SEC has entered an order declaring the
      Registration Statement effective under the 1933 Act at [ENTER TIME OF
      EFFECTIVENESS] on [ENTER DATE OF EFFECTIVENESS] and we have no knowledge, after
      telephonic inquiry of a member of the SEC’s staff, that any stop order
      suspending its effectiveness has been issued or that any proceedings for that
      purpose are pending before, or threatened by, the SEC and the Registrable
      Securities are available for resale under the 1933 Act pursuant to the
      Registration Statement.

     

    Very
      truly yours,

    

    By:__________________________________

    cc:  [LIST
      NAMES OF HOLDERS]

    

    
      
         
          

      

      
        25

        
          

        

      

      
         
          

      

    

    Annex
      B

     

    [__________

     

    Selling
      Securityholder Notice and Questionnaire

     

    The
      undersigned beneficial owner of common stock (the “Registrable
      Securities”) of [_______, a [_______ corporation (the “Company”),
      understands that the Company has filed or intends to file with the Securities
      and Exchange Commission (the “Commission”) a
      registration statement (the “Registration
      Statement”) for the registration and resale under Rule 415 of the
      Securities Act of 1933, as amended (the “Securities Act”), of
      the Registrable Securities, in accordance with the terms of the Amended and
      Restated Investor Rights Agreement (the “Registration Rights
      Agreement”) to which this document is annexed.  A copy of the
      Registration Rights Agreement is available from the Company upon request at
      the
      address set forth below.  All capitalized terms not otherwise defined
      herein shall have the meanings ascribed thereto in the Registration Rights
      Agreement.

     

    Certain
      legal consequences arise from being named as a selling securityholder in the
      Registration Statement and the related prospectus.  Accordingly,
      holders and beneficial owners of Registrable Securities are advised to consult
      their own securities law counsel regarding the consequences of being named
      or
      not being named as a selling securityholder in the Registration Statement and
      the related prospectus.

     

    NOTICE

     

    The
      undersigned beneficial owner (the “Selling
      Securityholder”) of Registrable Securities hereby elects to include the
      Registrable Securities owned by it in the Registration Statement.

     

    
      
         
          

      

      
        33

        
          

        

      

      
         
          

      

    

    The
      undersigned hereby provides the following information to the Company and
      represents and warrants that such information is accurate:

     

    QUESTIONNAIRE

     

    
      	
               
                

            	
              1.

            	
              Name.

            

    

     

    
      	
               
                

            	
              (a)

            	
              Full
                Legal Name of Selling
                Securityholder

            

    

     

    
      	 
              
	 
              

    

    

    
      	
               
                

            	
              (b)

            	
              Full
                Legal Name of Registered Holder (if not the same as (a) above) through
                which Registrable Securities are
                held:

            

    

     

    
      	 
              
	 
              

    

    

    
      	
               
                

            	
              (c)

            	
              Full
                Legal Name of Natural Control Person (which means a natural person
                who
                directly or indirectly alone or with others has power to vote or
                dispose
                of the securities covered by this
                Questionnaire):

            

    

     

    
      	 
              
	 
              

    

    

     

    
      	
               
                

            	
              2.  Address
                for Notices to Selling
                Securityholder:

            

    

     

    
      	 
              
	 
              
	 
              
	
              Telephone:

            
	
              Fax:

            
	
              Contact
                Person:

            

    

    

    
      	
               
                

            	
              3.  Broker-Dealer
                Status:

            

    

     

    
      	
               
                

            	
              (a)

            	
              Are
                you a broker-dealer?

            

    

     

    Yes                         No   

     

    
      	
               
                

            	
              (b)

            	
              If
                “yes” to Section 3(a), did you receive your Registrable Securities as
                compensation for investment banking services to the
                Company?

            

    

     

    Yes                         No   

     

    
      	
              Note:

            	
              If
                “no” to Section 3(b), the Commission’s staff has indicated that you should
                be identified as an underwriter in the Registration
                Statement.

            

    

     

    
      	
               
                

            	
              (c)

            	
              Are
                you an affiliate of a
                broker-dealer?

            

    

     

    Yes                         No   

     

    
      	
               
                

            	
              (d)

            	
              If
                you are an affiliate of a broker-dealer, do you certify that you
                purchased
                the Registrable Securities in the ordinary course of business, and
                at the
                time of the purchase of the Registrable Securities to be resold,
                you had
                no agreements or understandings, directly or indirectly, with any
                person
                to distribute the Registrable
                Securities?

            

    

     

    Yes                         No   

     

    
      	
              Note:

            	
              If
                “no” to Section 3(d), the Commission’s staff has indicated that you should
                be identified as an underwriter in the Registration
                Statement.

            

    

     

    
      	
               
                

            	
              4.  Beneficial
                Ownership of Securities of the Company Owned by the Selling
                Securityholder.

            

    

     

    Except
      as set forth below in this Item 4, the undersigned is not the beneficial or
      registered owner of any securities of the Company other than the securities
      issuable pursuant to the Purchase Agreement.

     

    
      	
               
                

            	
              (a)

            	
              Type
                and Amount of other securities beneficially owned by the Selling
                Securityholder:

            

    

     

    
      	 
              
	 
              
	 
              

    

    

    

     

    
      
         
          

      

      
        26

        
          

        

      

      
         
          

      

    

    
      	
               
                

            	
              5.  Relationships
                with the Company:

            

    

     

    Except
      as set forth below, neither the undersigned nor any of its affiliates, officers,
      directors or principal equity holders (owners of 5% of more of the equity
      securities of the undersigned) has held any position or office or has had any
      other material relationship with the Company (or its predecessors or affiliates)
      during the past three years.

     

    
      	
               
                

            	
              State
                any exceptions here:

            

    

     

    
      	 
              
	 
              
	 
              

    

    

     

    The
      undersigned agrees to promptly notify the Company of any inaccuracies or changes
      in the information provided herein that may occur subsequent to the date hereof
      at any time while the Registration Statement remains effective.

     

    By
      signing below, the undersigned consents to the disclosure of the information
      contained herein in its answers to Items 1 through 5 and the inclusion of such
      information in the Registration Statement and the related prospectus and any amendments or supplements
      thereto.  The undersigned understands that such information
      will be relied upon by the Company in connection with the preparation or
      amendment of the Registration Statement and the related prospectus.

     

    IN
      WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice
      and Questionnaire to be executed and delivered either in person or by its duly
      authorized agent.

     

    Date:                                                      Beneficial
      Owner:

    

    By:

    Name:

    Title:

    

    PLEASE
      FAX A COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN
      THE ORIGINAL BY OVERNIGHT MAIL, TO:

    

    

     

     

    
      
         
          

      

      
        27Unassociated Document

    
       

      
        EXHIBIT
          10.29

        
          

          

        

         

      

      EMPLOYMENT
        AGREEMENT

      

      THIS
        EMPLOYMENT AGREEMENT (“Agreement”) is made
        and effective as of this 4th
        day of
        January, 2007, between ACCESS Pharmaceuticals, Inc., a Delaware Corporation
        with
        a place of business at 2600 Stemmons Freeway, Suite 176, Dallas, Texas
        75207-2107 (“Company”), and
        Jeffrey B. Davis, an individual who resides at 33 Tall Oaks Drive, Summit,
        New
        Jersey 07901 (“Executive”).

       

      WHEREAS
        the Company desires to employ Executive and Executive desires to be employed
        by
        the Company, on terms set forth herein;

       

      NOW,
        THEREFORE, in consideration of the mutual agreements set forth herein, the
        parties agree as follows:

       

      1.             Term
        of Employment.
        Executive’s employment under this Agreement shall commence on January 4, 2007
        (“Effective
        Date”) and shall end on the third anniversary of the Effective Date
        (“ExpirationDate”)
        or such
        earlier date on which Executive’s employment terminates in accordance with
        Section 4 of this Agreement.  On the Expiration Date and each
        anniversary thereof, the Expiration Date shall be extended by one year unless
        (a) the Agreement has been earlier terminated under Section 4 or (b) either
        party gives written notice not less than 90 days prior to the then Expiration
        Date that the Agreement will not be extended. Notwithstanding any extension
        of
        the Expiration Date, Executive’s employment may terminate at any time in
        accordance with Section 4, below.

       

      2.             Nature
        of Duties. Executive
        shall during his employment hereunder be the Company’s Chief Executive Officer
        (“CEO”).  As
        such, Executive shall devote substantially all of his business time and effort
        to the performance of his duties for the Company, which he shall perform
        faithfully and to the best of his ability. Executive shall have all of the
        customary powers and duties associated with his position.  Executive
        shall be subject to the Company’s policies, procedures, and approval practices,
        as generally in effect from time to time for all employees of the Company.
        Executive will report directly to the Company’s board of directors (the “Board”).  Notwithstanding
        the foregoing, nothing contained herein shall preclude the Executive from
        (a)
        serving on the boards of directors of other companies or organizations with
        the
        approval of the Board (not to be unreasonably withheld) or serving on the
        boards
        of directors of not-for-profit companies or organizations without the approval
        of the Board, (b) investing in and managing passive investments, or (c) pursuing
        his personal, financial and legal affairs provided that such activity does
        not
        materially interfere with the performance of the Executive's obligations
        hereunder.

       

      
        	 
                	
                3.

              	
                Compensation
                  and Related
                  Matters.

              

      

       

      (a)           Base
        Salary. The Company shall
        pay Executive minimum base salary at an annual rate of
        $335,000.  Executive’s base salary shall be paid in conformity with
        the Company’s salary payment practices generally applicable to similarly
        situated Company employees.

       

      (b)          Discretionary
        Bonuses.
        Executive shall be covered by the cash bonus plan maintained from time to
        time
        by the Company and during each year of the term shall be afforded the
        opportunity thereunder to receive a target award of up to 50% of Executive’s
        annual base salary then in effect to be awarded upon the achievement of
        reasonable performance goals established by the Board within thirty (30)
        days of
        the beginning of such year, which bonus, if any, shall be payable in accordance
        with the cash bonus plan but in no event later than ninety (90) days of the
        end
        of such year.  Upon the occurrence of a Change of Control during the
        term, Executive shall receive a pro rata annual bonus for that portion of
        the
        year within which the Change of Control occurs in addition to other compensation
        due to Executive upon a Change of Control (as hereinafter defined) as provided
        in this Agreement.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

      (c)           Stock
        Options. Upon
        commencement of employment, Executive shall be granted an option (the “Option”)
        to purchase 600,000 shares of the Company’s common stock.  The
        exercise price of the Option shall be equal to the fair market value of the
        Company’s common stock on the date of grant, which the Company has determined to
        be the closing price of the Company’s common stock as of January 3, 2008
        ($3.15), which is the last trading day preceding the date of
        grant.  The Option shall vest 25% on the one year anniversary of the
        date hereof and monthly thereafter over a period of 24 months, and otherwise
        shall be subject to the terms of option agreements which shall provide, among
        other standard provisions:

       

      (i)
        that
        the Option shall be comprised of (A) an incentive stock option for the number
        of
        shares the Company’s common stock available for issuance under the Company’s
        2005 Equity Incentive Plan as of the date hereof, and (B) a non-statutory
        stock
        option for the balance of the shares issuable upon exercise of the Option;
        and

       

      (ii)  for
        acceleration of the Option upon or following the occurrence of a Change of
        Control (as defined below) or upon a discharge other than for Cause (as provided
        in Section 4 below).

       

      (d)           Tax
        Benefits.   If a Change of Control occurs during the term
        which prevents any Option which has Incentive Stock Option (“ISO”) designation,
        or any other annual ISO option grant to Executive during the term, from
        receiving favorable tax treatment under Section 422 of the Internal Revenue
        Code
        of 1986, as amended, Executive shall receive a complete tax make-whole from
        the
        Company or its successor and shall be held harmless from the loss of favorable
        tax treatment.   Further, upon a Change of Control, Executive
        shall receive a complete tax make-whole for any and all excise taxes due
        or
        payable under Section 4999 of the Internal Revenue Code of 1986, as amended,
        and
        any state and/or local taxes payable under similar provisions of state and/or
        local law, in each case, with any interest and/or penalties payable with
        respect
        thereto.

       

      (e)           Standard
        Benefits. During his
        employment, Executive shall be entitled to participate in all employee benefit
        plans and programs to the same extent generally available to similarly situated
        employees of the Company, in accordance with the terms of those plans and
        programs.

       

      (f)           Vacation.
        Executive shall be
        entitled to four (4) weeks paid vacation per year, which shall be pro-rated
        for
        partial years. Unused vacation days will carry over pursuant to the terms
        set
        forth in the Company’s Employee Handbook. Notwithstanding anything herein to the
        contrary, Executive may not take more than two (2) weeks vacation during
        any
        twelve (12) week period without the Company’s prior written
        permission.

       

      (g)            Expenses.
        Executive shall be
        entitled to receive prompt reimbursement for all reasonable and customary
        travel
        and business expenses he incurs in connection with his employment, but he
        must
        incur and account for those expenses in accordance with the policies and
        procedures established by the Company.

       

      (g)           Place
        of Performance. In
        connection with his employment by the Company, unless otherwise agreed by
        the
        Executive, the Executive shall be based at an office of the Company in New
        York
        City, except for travel reasonably required for Company business (the "Place
        of
        Performance").

       

      
        	 
                	
                4.

              	
                Termination.

              

      

      (h)           Rights
        and Duties. If
        Executive’s employment is terminated he shall be entitled to the amounts or
        benefits shown on the applicable row of the following table, subject to the
        balance of this Section 4, beyond which the Company and Executive shall have
        no
        further obligations to each other, except Executive’s confidentiality and other
        obligations under Section 6, the parties’ mutual arbitration obligations under
        Section 7, as otherwise set forth in this Agreement or as set forth in any
        written agreement the parties subsequently enter into.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      
        	
                DISCHARGE
                  FOR CAUSE

              	
                Payment
                  when due of any unpaid base salary, expense reimbursements, and
                  vacation
                  days accrued prior to termination of employment. Executive shall
                  forfeit
                  all vested and unvested stock options issued or issuable under
                  Section
                  3(c) of this Agreement, pursuant to the terms of the Option Award
                  Agreement.

              
	
                DISCHARGE
                  OTHER THAN FOR CAUSE

              	
                Same
                  as for “Discharge For Cause” EXCEPT that, in exchange for Executive’s
                  execution of a release in accordance with this Section 4, Executive
                  shall
                  be entitled to the following special benefits: (A) a lump sum in
                  cash,
                  payable within ten (10) business days after the effective date
                  of such
                  event, equal to two times the sum of Executive’s then-current base salary,
                  plus his then average annual bonus for the preceding two years
                  (or, if
                  applicable, using the annual bonus target for such occurrences
                  prior to
                  receipt of the first annual bonus), pursuant to Section 3 of this
                  Agreement, and (B) all of Executive’s outstanding stock options issued or
                  issuable under Section 3(c) of this Agreement, shall immediately
                  vest and
                  become exercisable and Executive shall have the full term of the
                  option to
                  exercise any of his stock options, pursuant to the terms of the
                  Option
                  Award Agreement.

              
	
                RESIGNATION
                  WITHOUT GOOD REASON

              	
                Same
                  as for “Discharge for Cause.”

              
	
                RESIGNATION
                  WITH GOOD REASON

              	
                Same
                  as for “Discharge Other Than For Cause.”

              
	
                DISABILITY

              	
                Same
                  as for “Discharge For Cause” EXCEPT that salary continuation will be
                  reduced by any amounts received by Executive under any Company-sponsored
                  disability benefits plan, and in exchange for Executive’s execution of a
                  release in accordance with this Section 4, all of Executive’s outstanding
                  vested stock options shall be exercisable pursuant to the terms
                  of the
                  Option Award Agreement.

              
	
                DEATH

              	
                Same
                  as for “Discharge for Cause” EXCEPT that, in exchange for the execution of
                  a release by Executive’s estate in accordance with this Section 4,
                  continuation of Executive’s base salary for six (6) months after the date
                  of termination and Executive’s outstanding vested stock options shall be
                  exercisable pursuant to the terms of the Option Award
                  Agreement.

              

      

       

       

      (i)           Discharge
        for Cause. The
        Company may terminate Executive’s employment at any time if it believes in good
        faith that it has Cause to terminate his employment. “Cause” shall
        mean:

       

      (i)           Fraud
        and Dishonesty.
        Executive’s commission of a willful act of fraud or dishonesty, the purpose or
        effect of which materially and adversely affects the Company or its subsidiaries
        and affiliates (“Group”).

       

      (ii)          Unlawful
        Conduct. Executive’s
        engaging in conduct that is unlawful.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

      (iii)         Reckless
        Conduct. Executive’s
        engaging in intentional or reckless misconduct or gross negligence in connection
        with any property or activity of the Group, the purpose or effect of which
        materially and adversely affects the Group.

       

      (iv)         Breach
        of Agreement.
        Executive’s material breach of any of his obligations under this Agreement
        (other than by reason of physical or mental illness, injury, or
        condition).

       

      (v)          Failure
        to Perform Duties.
        Executive’s continued failure or refusal to attempt in good faith to perform his
        job duties under this Agreement or to follow the reasonable directions of
        the
        Board (other than by reason of physical or mental illness, injury, or condition)
        after having received thirty (30) days’ notice from the Board of his failure to
        do so and an opportunity to cure.

       

      (vi)         Barred
        from Office.
        Executive’s becoming barred or prohibited by the U.S. Securities and Exchange
        Commission from holding his position with the Company.

       

      (j)            Termination
        for Disability.
        Except as prohibited by applicable law, the Company may terminate Executive’s
        employment on account of Disability, or may transfer him to inactive employment
        status, which shall have the same effect under this Agreement as a discharge
        “other than for Cause.” “Disability”
means a
        physical or mental illness, injury, or condition that prevents Executive
        from
        performing substantially all of his duties under this Agreement for at least
        90
        consecutive calendar days or for at least 120 calendar days, whether or not
        consecutive, in any 365 calendar day period.

       

      (k)           Discharge
        Other Than for
        Cause. The Company may terminate Executive’s employment at any time for
        any reason, and without advance notice. If Executive is discharged by the
        Company for a reason “other than for Cause”, for “death” or for “Disability”, he
        will only receive the special benefits provided for such events under Section
        4(a) if he (or his estate, as the case may be) signs a separation agreement
        and
        general release in a form supplied by the Company within 60 days after his
        employment ends and he does not thereafter properly revoke the
        release.

       

      (l)           Resignation.
        Executive
        promises not to resign his employment without providing the Company at least
        sixty (60) days advance written notice.  If Executive resigns “other
        than for Good Reason”, the Company may accept his resignation effective on the
        date set forth in his notice or any earlier date.  If Executive
        resigns for Good Reason, his employment will end on his last date of work
        and he
        will receive the benefits to which he is entitled under Section 4(a), but
        he
        only will receive special benefits conditioned on his signing a separation
        agreement and general release in a form supplied by the Company within 60
        days
        after his employment ends and he does not thereafter properly revoke the
        release. “Good
        Reason” means that, without his express written consent, one or more of
        the following events occurred after his execution of this
        Agreement:

       

      (i)             Demotion.
        Executive’s duties
        or responsibilities are substantially and adversely diminished from those
        in
        effect immediately before such event other than merely as a result of the
        Company ceasing to be a public company.

       

      
        	 
                	
                (ii)

              	
                Pay
                  Cut. Executive’s
                  annual base salary is reduced.

              

      

       

      (iii)           Breach
        of Promise. The Company
        materially breaches this Agreement or fails to pay Executive any present
        or
        deferred compensation within 7 days after it is due.

       

      (iv)         Change
        of Control. There
        occurs a “Change of
        Control,” which means the occurrence of any of the following: (i) the
        acquisition, directly or indirectly, by any individual or entity or group
        (as
        such term is used in Section 13(d)(3) of the Exchange Act) of beneficial
        ownership (as defined in Rule 13d-3 under the Exchange Act, except that such
        individual or entity shall be deemed to have beneficial ownership of all
        shares
        that any such individual or entity has the right to acquire without the
        happening or failure to happen of a material condition or contingency, other
        than the passage of time) of more than 50% of the aggregate outstanding voting
        power of capital stock of the Corporation in respect of the general power
        to
        elect directors; or (ii) (A) the Corporation consolidates with or merges
        into
        another entity or sells all or substantially all of its assets to any individual
        or entity, or (B) any corporation consolidates with or merges into the
        Corporation, which in either event (A) or (B) is pursuant to a transaction
        in
        which the holders of the Corporation's voting capital stock in respect of
        the
        general power to elect directors immediately prior to such transaction do
        not
        own, immediately following such transaction, at least a majority of the voting
        capital stock in respect of the general power to elect directors of the
        surviving corporation or the person or entity which owns the assets so
        sold.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

      (v)          Notice
        of Prospective Action.
        Executive is officially notified (or it is officially announced) that the
        Company will take any of the actions listed above during the term of this
        Agreement.

       

      However,
        an event that is or would constitute Good Reason shall cease to be Good Reason
        if: (1) Executive does not terminate employment within ten (10) days after
        the
        event occurs with knowledge of Executive (except for a Change of Control);
        or
        (2) the Company reverses the action or cures the default that constitutes
        Good
        Reason within 30 days after Executive notifies it

       

      in
        writing that Good Reason exists before Executive terminates employment If
        Executive has Good Reason to terminate employment, he may do so even if he
        is on
        a leave of absence due to physical or mental illness or any other reason,
        but he
        must do so before his actual or constructive Disability termination as defined
        herein.

       

      (m)          Disputes
        Under This Section.
        All disputes relating to this Agreement, including disputes relating to this
        Section 4, shall be resolved by final and binding arbitration under Section
        7.

       

      4.             No
        Other Termination
        Compensation. Except as specifically provided in this Agreement or the
        Option Agreement to be entered into between the parties or any future amendment
        or restatement of either agreement, upon termination of this Agreement for
        any
        reason Executive shall not be entitled to any severance pay or to any other
        compensation or payments (by way of salary, damages or otherwise) of any
        nature
        relating to this Agreement or otherwise relating to or arising out of his
        employment by the Company.

       

      5.             Confidentiality.
        During the
        term of Executive’s employment, in exchange for his promises to use such
        information solely for the Company’s benefit, the Company will provide Executive
        with Confidential Information concerning, among other things, its business,
        operations, customers, vendors, owners, investors, and business partners.
“Confidential
        Information” refers to information not generally known by others in the
        form in which it is used by the Company, and which gives the Company a
        competitive advantage over other companies which do not have access to this
        information, including secret, confidential, or proprietary information or
        trade
        secrets of the Company and its subsidiaries and affiliates, conveyed orally
        or
        reduced to a tangible form in any medium, including information concerning
        the
        operations, future plans, customers, business models, strategies, and business
        methods of the Company and its subsidiaries and affiliates, as well as
        information about the Company’s customers, clients and business partners and
        their respective operations and confidential information. “Confidential
        Information” does not include information that (i) Executive knew prior to his
        employment with the Company or any predecessor company, (ii) subsequently
        came
        into Executive’s possession other than through his work for the Company or any
        predecessor company and not as a result of a breach of any duty owed to the
        Company, (iii) is generally known within the relevant industry; or (d) any
        prior
        knowledge, information or know-how which Executive legally obtained from
        a
        source other than the Company

       

      (a)           Promise
        Not to Disclose.
        Executive promises never to use or disclose any Confidential Information
        before
        it has become generally known within the relevant industry through no fault
        of
        Executive. Notwithstanding this paragraph, Executive may disclose Confidential
        Information (i) during his employment for the benefit of the Company, (ii)
        as
        required to do so by court order, subpoena, or otherwise as required by law,
        provided that upon receiving such order, subpoena, or request and prior to
        disclosure, to the extent permitted by law Executive shall provide written
        notice to the Company of such order, subpoena, or request and of the content
        of
        any testimony or information to be disclosed and shall cooperate fully with
        the
        Company to lawfully resist disclosure of the information, and (iii) to an
        attorney for the purpose of securing professional advice.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

      (b)           Promise
        Not to Solicit.
        Executive agrees that, during his employment with the Company and for twelve
        (12) months after his termination for any reason

                                                                                                              

      (together,
        the “Restricted
        Period”): (1) as to any client or business partner of the Company with
        whom Executive had dealings or about whom Executive acquired confidential
        information during his employment, Executive will not solicit, attempt to
        solicit, assist others to solicit, or accept any unsolicited request from
        the
        client or business partner to do business with any person or entity other
        than
        the Company or its affiliates; and (2) Executive will not solicit, attempt
        to
        solicit, assist others to solicit, hire, or assist others to hire for employment
        any person who is, or within the preceding twelve (12) months was, an officer,
        manager, employee, or consultant of the Company. Executive agrees that the
        restrictions set forth in this paragraph do not and will not prohibit his
        from
        engaging in his livelihood and do not foreclose his working with clients
        or
        business partners not identified in this paragraph.

       

      (c)           Promise
        Not to Engage in Certain
        Employment. Executive agrees that, during the Restricted Period, he will
        not, without the prior written consent of the Company, accept any employment;
        provide any services, advice or information; or assist or engage in any activity
        (whether as an employee, consultant, or in any other capacity, whether paid
        or
        unpaid) with any business or other entity in the business, directly or
        indirectly, for profit or not, of developing, with a majority of its revenue
        derived from distributing or marketing compounds or technologies for the
        treatment of cancer in the United States.

       

      (d)           Return
        of Information. When
        Executive’s employment with the Company ends, he will promptly deliver to the
        Company, or, at its written instruction, destroy, all documents, data, drawings,
        manuals, letters, notes, reports, electronic mail, recordings, and copies
        thereof, of or pertaining to it or any other Group member in his possession
        or
        control. Notwithstanding the foregoing, Executive may retain his personal
        effects, files, benefit information, or other property to the extent such
        materials do not contain any of the Company’s Confidential Information. In
        addition, during his employment with the Company or the Group and thereafter,
        Executive agrees to meet with Company personnel and, based on knowledge or
        insights he gained during his employment with the Company and the Group,
        answer
        any question they may have related to the Company or the Group as reasonably
        requested.

       

      (e)           Intellectual
        Property.
        Intellectual property (including such things as all ideas, concepts, inventions,
        plans, developments, software, data, configurations, materials (whether written
        or machine-readable), designs, drawings, illustrations, and photographs,
        that
        may be protectable, in whole or in part, under any patent, copyright, trademark,
        trade secret, or other intellectual property law), developed, created,
        conceived, made, or reduced to practice during Executive’s employment with the
        Company (except intellectual property that has no relation to the Group or
        any
        Group customer that Executive developed, etc., purely on his own time and
        at his
        own expense), shall be the sole and exclusive property of the Company, and
        Executive hereby assigns all rights, title, and interest in any such
        intellectual property to the Company.

       

      (f)            Enforcement
        of This Section.
        This section shall survive the termination of this Agreement or Executive’s
        employment for any reason. Executive acknowledges that (a) this section’s terms
        are reasonable and necessary to protect the Company’s legitimate interests, (b)
        this section’s restrictions will not prevent his from earning or seeking a
        livelihood, (c) this section’s restrictions shall apply wherever permitted by
        law, and (d) the violation of any of this section’s terms would irreparably harm
        the Company. Accordingly,

       

      Executive
        agrees that, if she violates any of the provisions of this section, the Company
        or any Group member shall be entitled to, in addition to other remedies
        available to it, an injunction to be issued by any court of competent
        jurisdiction restraining Executive from committing or continuing any such
        violation, without the need to prove the inadequacy of money damages or post
        any
        bond or for any other undertaking.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

      6.             Arbitration
        of Disputes.
        Except as expressly prohibited by law and except for the Company’s right to seek
        injunctive relief as set forth in Section 6(f), all disputes between the
        Company
        and Executive (“Arbitrable Disputes”)
        are to be resolved by final and binding arbitration in accordance with this
        Section 7. This section shall remain in effect after the termination of this
        Agreement or Executive’s employment.

       

      (a)           Scope
        of Agreement. This
        arbitration agreement applies to, among other things, disputes concerning
        Executive’s employment with and/or termination from the Company; the validity,
        interpretation, enforceability or effect of this Agreement or alleged violations
        of it; claims of discrimination under federal or state law; or other statutory
        or common law claims.

       

      (b)           The
        Arbitration. The
        arbitration shall take place under the auspices of the American Arbitration
        Association (“AAA”) in its
        office
        nearest to the location where Executive last worked for the Company and
        conducted in accordance with the AAA’s National Rules for the Resolution of
        Employment Disputes then in effect before an experienced employment law
        arbitrator licensed to practice law in that jurisdiction who has been selected
        in accordance with such rules. The arbitrator may not modify or change this
        Agreement in any way except as expressly set forth herein. The arbitration
        shall
        be governed by the substantive law of the State of New York (excluding where
        it
        mandates the use of another jurisdiction’s laws).

       

      (c)           Fees
        and Expenses. Regardless
        of which party initiates the arbitration, the non-prevailing party in any
        dispute between the Company and Executive shall promptly pay the prevailing
        party for any and all reasonable costs and expenses of such dispute upon
        the
        parties’ receipt of the final and binding resolution of such
        dispute.

       

      (d)           Exclusive
        Remedy. The
        arbitration in this manner shall be the exclusive remedy for any Arbitrable
        Dispute.

       

      (e)           Judicial
        Enforcement. Nothing
        in this Section 7 shall preclude any party to this agreement from seeking
        judicial enforcement of an arbitrator’s award. Judgment may be entered on the
        arbitrator’s award in any court having jurisdiction.

       

      7.             Amendment.
        No provisions of
        this Agreement may be modified, waived, or discharged except by a written
        document signed by a duly authorized Company officer and

       

      Executive.
        A waiver of any conditions or provisions of this Agreement in a given instance
        shall not be deemed a waiver of such conditions or provisions at any other
        time
        in the future.

       

      8.             Notices.
        For all purposes of
        this Agreement, all communications, including, without limitation, notices,
        consents, request or approvals, required or permitted to be given hereunder
        will
        be in writing and will be deemed to have been duly given when hand delivered
        or
        dispatched by electronic facsimile transmission (with receipt thereof
        confirmed), or five business days after having been mailed by United States
        registered or certified mail, return receipt requested, postage prepaid,
        or
        three business days after having been sent by a nationally recognized overnight
        courier service such as Federal Express or UPS, addressed to the Company
        (to the
        attention of the Secretary of the Company) at its principal executive offices
        and to Executive at his principal residence, or to such other address as
        any
        party may have furnished to the other in writing and in accordance herewith,
        except that notices of changes of address shall be effective only upon
        receipt.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

      9.             Choice
        of Law. The validity,
        interpretation, construction, and performance of this Agreement shall be
        governed by the laws of the State of New York (excluding any that mandate
        the
        use of another jurisdiction’s laws).

       

      10.          Successors.
        This Agreement
        shall be binding upon, and shall inure to the benefit of, Executive and his
        estate, but Executive may not assign or pledge this Agreement or any rights
        arising under it, except to the extent permitted under the terms of the benefit
        plans in which she participates. Without Executive’s consent, the Company may
        assign this Agreement to any affiliate or to a successor to substantially
        all
        the business and assets of the Company.

       

      11.          Taxes.
        The Company shall
        withhold taxes from payments it makes pursuant to this Agreement as it
        reasonably determines to be required by applicable law.

       

      12.          Validity.
        The invalidity or
        unenforceability of any provision of this Agreement shall not affect the
        validity or enforceability of any other provision of this Agreement, which
        shall
        remain in full force and effect.

       

      13.          Counterparts.
        This Agreement
        may be executed in one or more counterparts, each of which shall be deemed
        to be
        an original but all of which together shall constitute the same
        instrument.

       

      14.          Entire
        Agreement. All oral or
        written agreements or representations, express or implied, with respect to
        the
        subject matter of this Agreement are set forth in this Agreement. All prior
        written employment agreements between Executive and the Company are hereby
        declared null and void, and of no further effect.

       

       

      
        	
                Date:
                  January 4, 2007

              	
                ACCESS
                  PHARMACEUTICALS, INC.

              

      

       

      
        	
                 
                  By:

              	
                /s/
                  David P.
                  Luci

              

      

      
        	 
                	
                Name:  David
                  P. Luci

              

      

      
        	 
                	
                Title:
                  Director, Chairman of Compensation
                  Committee

              

      

       

      
        	
                Date:
                  January 4, 2007

              	
                /s/
                  Jeffrey B.
                  Davis

              

      

      
        	 
                	
                Jeffrey
                  B. Davis

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}]]